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ABSTRACT OF THE THESIS
Phenotyping Double Transgenic Mouse Models of Alzheimer’s that Express Human APP
and ApoE3 or ApoE4
by
Shina Halavi
Doctor of Philosophy, Graduate Program in Clinical Psychology
Loma Linda University, June 2016
Dr. Richard Hartman, Chairperson
Alzheimer’s disease (AD) is a neurodegenerative disorder that causes progressive
cognitive and behavioral problems resulting from a build-up of amyloid-beta (Aβ)
plaques in the brain. The degree of neuropathology is partially related to apolipoprotein E
(apoE), a fat-binding protein involved in transporting cholesterol to neurons. The APOE
gene, which codes for the production of apoE, has several alleles in humans, including
APOE3 (E3; the most common) and APOE4 (E4; which is associated with a high risk for
developing AD).
Transgenic mouse models of AD are commonly used to study the
neuropathological processes behind the development of Aβ plaques, neurodegeneration,
and associated behavioral deficits. The current study was designed to determine whether
expression of E4 in a transgenic mouse model of AD (the PDAPP mouse) alters these
processes in a way that replicates the effects observed in humans with E4. The brains of
male PDAPP x APOE3 mice (PDAPP:E3; n=5) were compared to those of PDAPP x
APOE4 mice (PDAPP:E4; n=4) by staining tissue sections with HJ3.4, thioflavin-S, and
4’,6-diamidino-2-phenylindole (DAPI) to quantify diffuse Aβ, fibrillar Aβ, and cellular
count, respectively.
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PDAPP:E4 mice had more total Aβ in the CA1 of the hippocampus and dorsal
cortex. Also, a trend suggested PDAPP:E4 mice had a lower cellular density in the CA1
and dorsal cortex than PDAPP:E3 mice. Importantly, more Alzheimer’s-like
neuropathology was generally associated with worse behavioral deficits. Since these
results replicate aspects of human AD (plaque load, lower cellular density, and behavioral
deficits), the expression of human APOE in transgenic mice may improve their use as a
model system for understanding the processes involved in the development of AD and
therapeutic strategies for dealing with the disease.

xii

CHAPTER ONE
SPECIFIC AIMS
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder
characterized by global cognitive decline involving memory, orientation, judgment and
reasoning. AD is the most common cause of dementia, a decline in mental ability due to a
brain disease or injury, in the elderly. In 2014, the Alzheimer’s Association estimated that
5.2 million Americans had AD (2014 Alzheimer’s Disease Facts and Figures, 2014). In
familial AD (FAD, or early-onset AD), which is directly caused by an autosomal
dominant gene mutation, an abnormal variation of the amyloid precursor protein gene
(APP) gets cleaved by β- and γ-secretase, releasing a free Aβ peptide from the protein.
These Aβ peptides aggregate, which lead to the accumulation of Aβ plaques in the brain,
which eventually causes neuronal dysfunction in the brain. This form of AD accounts for
about 1-5% of all cases of AD (Demattos, Bales, Paul, & Holtzman, 2000).
In the more common (“sporadic”, or late onset) form of AD, genes can also
influence the risk of developing the disease. The most-studied gene of susceptibility for
sporadic AD is the APOE gene, which codes for the protein apolipoprotein E (apoE).
APOE plays a role in the pathogenesis of late-onset AD, and has three major alleles:
APOE2 (E2), APOE3 (E3), and APOE4 (E4). Alleles are alternative forms of a gene that
arise by a mutation and are found on the same place on the chromosome. Each individual
carries two copies of APOE, one from each parent. The likelihood of someone
developing AD is highly dependent upon which of these three alleles they carry (Corder
et al., 1993). The current study addresses E4, which is known to increase the risk and
decrease the age of onset of AD, and E3, which encodes for the most common isoform
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(apoE3) and acts as a neutral allele, not influencing one’s risk of developing the disease
by using a double-transgenic mouse model. ApoE “knockout” (KO) mice, which do not
express APOE, had human E3 and E4 inserted into their genomes via “knockin” (KI)
technology. These models address a novel way of producing double-transgenic mice,
representing a “cleaner” double-transgenic mouse model compared to what is normally
seen in the literature (e.g., Hartman et al., 2002). This methodology differs from what is
normally seen in the literature in that human APOE was not placed in a random location,
but in the exact location within the mouse genome from which murine APOE was
removed. Hypothetically, this resulted in an Aβ and APOE interaction more similar to
what is seen in humans with AD. These mice were then crossbred with PDAPP
transgenic mice, the first successful AD transgenic mouse model that contained an FADassociated mutation (Games et al., 1995).
My hypothesis is that PDAPP mice that also express human E4 will have more
Alzheimer’s-like neuropathology than PDAPP mice that express human E3. The
objective of this study is to determine whether targeted expression of human APOE alters
neuropathology in a transgenic mouse model of AD by establishing a baseline
neuropathological and behavioral data for a new double-transgenic mouse model of AD.
Neuropathological assessment of PDAPP mice expressing human E3 and E4 has
consisted of thioflavin-S staining (Kelly R. Bales et al., 1999; Fagan et al., 2002; Richard
E Hartman et al., 2002). Bales et al. (1999) found that the amount of fibrillar amyloid
(thioflavin-S-positive material) was significantly greater in PDAPP:E4 mice than in the
PDAPP:E3 mice. Fagan et al. (2002) found that PDAPP:E4 mice had a greater Aβ burden
and an earlier age of onset than the PDAPP:E3 mice. Lastly, Hartman et al. (2002)
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assessed the effects of TBI (traumatic brain injury) in PDAPP:E4 and PDAPP:E3 mice
and only found thioflavin-S-positive Aβ (amyloid) in the PDAPP/ε4 mice. Behavioral
assessments of APOE transgenic mice have consisted of spatial learning and memory
tests (rotating holeboard, radial arm maze, and water maze) and tests of sensorimotor
capabilities and emotionality (locomotor activity and elevated plus maze) (R E Hartman
et al., 2001). This objective will be met by addressing the following three aims.

Aim 1: To determine whether expression of human APOE will alter plaque load in
the hippocampus and dorsal cortex of double-transgenic mice that model aspects of
AD. Hypothesis: PDAPP mice that also express human E4 will have more amyloid-beta
(Aβ) plaques in their brains than PDAPP mice that also express human E3. Rationale:
Humans with 1 or 2 copies of the E4 gene generally have worse Alzheimer’s
neuropathology than humans without E4.

Aim 2: To determine whether expression of human APOE will alter cellular density
in the CA1 region of the hippocampus and dorsal cortex of transgenic mice that
model aspects of Alzheimer’s disease. Hypothesis: PDAPP mice that also express
human E3 will have a lower cellular density in the CA1 region of the hippocampus and
dorsal cortices than PDAPP mice that also express human E3. Rationale: Humans with 1
or 2 copies of the E4 gene generally have more Aβ aggregates, leading to a greater
cellular loss.
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Aim 3: To determine whether the degree of neuropathology is correlated with
behavioral deficits observed in these mice. Hypothesis: Mice with more Alzheimer’slike neuropathology (specifically Aβ plaques and/or neuronal loss) will have worse
behavioral deficits. Rationale: The formation of Aβ plaques in humans is thought to
ultimately lead to the neuronal dysfunction and cognitive deficits observed in AD.
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CHAPTER TWO
SIGNIFICANCE
Demographics
In 2014, the Alzheimer’s Association reported that AD affects 11% of people 65
years and older and 32% of people 85 years and older (2014 Alzheimer’s Disease Facts
and Figures, 2014). In 2012, the Alzheimer’s Association estimated that, of those with
AD, 4% are under the age of 65, 6% are 65 to 74 years of age, 44% are 75 to 84 years of
age, and 46% are 85 years or older (2012 Alzheimer’s disease facts and figures, 2012). In
addition to the high prevalence of AD (number of existing cases in a population at a
given time), the estimated annual incidence (rate of developing AD in a one-year period)
of AD appears to increase dramatically with age. The Journal of Alzheimer Disease and
Associated Disorders estimated that by the year 2050, there would be 80 new cases of
AD per 1,000 people age 65 to 74, to 282 new cases per 1,000 people age 75 to 84, to 598
new cases per 1,000 people over age 85. This increasing incidence rate is due to an aging
population and social and environmental factors. The increasingly high prevalence and
incidence rate of this disease is concerning, emphasizing the importance of the
development of effective treatments.

Neuropathology
Plaques
Amyloid plaques are a neuropathological characteristic of AD (Calhoun et al.,
1998). Amyloid plaques are formed by Aβ, a 39-to-43-amino-acid-long peptide derived
by the proteolytic processing of APP. When APP is cleaved by β- and γ-secretase, Aβ
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gets released into the extracellular space (Figure 1; Haass et al., 1992; Martin et al., 1995;
Shoji et al., 2014; Wertkin et al., 1993; Yang, Knauer, Burdick, & Glabe, 1995),
normally via synaptic activity (Kamenetz et al., 2003). Another enzyme, α-secretase,
serves as a neuroprotectant by cleaving the APP molecule within the Aβ peptide region,
preventing the formation of Aβ plaques.

Figure 1. β- and γ-secretase cleave APP at specific sites to form toxic Aβ. Retrieved
from http://commons.wikimedia.org/wiki/File:APP_cleavage_produce_toxic_Abeta.png.

The two most common isoforms of Aβ are Aβ40 and Aβ42, which only differ by
two amino acids (Yan & Wang, 2006). Aβ40 is a 40-residue soluble peptide, which
represents the most abundant Aβ isoform, both in the normal and AD brain (Mori, Takio,
Ogawarag, & Selkoe, 1992), especially in sporadic AD (Näslund et al., 1994). Aβ42 is a
42-residue insoluble peptide, which is more closely linked to FAD (Younkin, 1998). Aβ42
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has shown to form insoluble amyloid fibrils more rapidly than the abundant Aβ40, making
it more susceptible to fibril formation in both humans and mice (Hartman et al., 2005;
Jarrett, Berger, & Lansbury, 1993).
Amyloid fibrils are formed by soluble proteins that aggregate to form insoluble
fibers, which are resistant to degradation (Rambaran & Serpell, 2008). Amyloid is
dominated by a β-pleated sheet structure, which consists of the protein being folded in a
certain way that gives it a very stable structure (Rambaran & Serpell, 2008). This process
is also seen in the production of spider silk, where soluble proteins are converted to
“stronger than steel” insoluble fibers (Kenney, Knight, Wise, & Vollrath, 2002). The
spider silk also takes on a β-pleated sheet structure (Kenney et al., 2002). Aβ42 is
particularly known to be neurotoxic (Elder, Sosa, & Gasperi, 2010; Yan & Wang, 2006)
and more prone to aggregation than Aβ40 (Yan & Wang, 2006). Aβ42 has specifically been
described as the more toxic form of Aβ (Querfurth & Laferla, 2010; reviewed [Tai,
Youmans, Jungbauer, Yu, & Ladu, 2011]).
The elevated Aβ levels in the brain drive the conversion of soluble forms of Aβ to
aggregated forms of Aβ (Holtzman, 2004), forming amyloid plaques within the
extracellular spaces of the brain. Amyloid plaques exist in different conformations. These
conformations include diffuse plaques, compact plaques, and neuritic plaques in
increasing chronological and neuropathological order (Groen, Liu, Ikonen, & Kadish,
2003). Diffuse plaques, which contain nonfibrillar Aβ, develop from aggregated soluble
peptides. Diffuse plaques are displayed as amorphous wisps of amyloid that lack a central
core and are probably not neurotoxic. The reason they are important to be studied is
because of their progression into neurotoxic plaques. Diffuse plaques have a low β-
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pleated sheet content (Holtzman, 2004). Compact “amyloid” plaques are composed of a
dense thioflavin-S-positive core, and neuritic plaques are identified as amyloid plaques
surrounded by a ring of dystrophic neurites (axons/dendrites; (Groen et al., 2003).
Compact and neuritic plaques contain fibrillar Aβ, which possess a high β-pleated sheet
structure (Holtzman, 2004; Mattson, 1997).
As described by Games et al. (1995), it is the enhanced production of Aβ peptide
(specifically Aβ42) that leads to the pathological deposition of amyloid in the brain. It is
the accumulation of these Aβ deposits in the brain that leads to the development of the
Aβ plaques that eventually lead to neuronal dysfunction in the brain (Koudinov, Berezov,
& Koudinova, 2001). Although the mechanism of amyloid neurotoxicity remains unclear
(Stern et al., 2004; reviewed [Tai et al., 2011]; Verghese, Castellano, & Holtzman, 2011),
research suggests that Aβ has been found in mitochondrial membranes, impairing
mitochondrial function (Lustbader et al., 2004; Mattson, Partin, & Begley, 1998; Reddy,
2009). Mitochondria are the major source of energy for normal functioning brain cells.
However, evidence linking Aβ toxicity with mitochondrial dysfunction is still limited to
in vitro studies. Stern et al. (2004) has also suggested that the Aβ plaques disrupt the
synchrony of convergent inputs, reducing the ability of neurons to successfully integrate
and propagate information. Amyloid deposition in the brain’s parenchyma and cerebral
blood vessels is one of the recognized neuropathological features of AD. These distinct
neuropathological phenotypes will be quantified to assess the degree of Alzheimer’s-like
pathology in the current study.
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NFTs and NTs
Another neuropathological hallmark of AD is intracellular neurofibrillary tangles
(NFTs) and neuropil threads (NTs), which consist of abnormal phosphorylated Tau
proteins (Richard E Hartman et al., 2005). Tau proteins stabilize microtubules, a
component of the cytoskeleton. When tau becomes hyperphosphorylated (multiple
phosphates attached to it), tau becomes insoluble and lacks affinity for microtubules. This
causes the hyperphosphorylated tau to detach and self-aggregate and microtubules to
destabilize, which can lead to the death of the cell.

Cell Loss
Although neuronal loss does not belong to the diagnostic criteria of AD
(Duyckaerts, Potier, & Delatour, 2007), it is considered an important pathological
component of the disease. Several studies have addressed both the presence and absence
of cellular loss in the hippocampus. Hippocampal cell loss was observed in vitro in both
human and animal models (Estus et al., 1997; Friedrich et al., 2010; Ji et al., 2002; Loo et
al., 1993) as well as in vivo in mouse models (Calhoun et al., 1998; Casas et al., 2004;
LaFerla, Hall, Ngo, & Jay, 1996; Schmitz et al., 2004) in some studies, but not observed
in other in vivo mouse studies (Irizarry et al., 1997; Jawhar, Trawicka, Jenneckens, Bayer,
& Wirths, 2012; Takeuchi et al., 2000). This contradicting evidence suggests that
hippocampal cellular loss in AD is something to be further investigated.

Familial vs. Sporadic AD
AD can present as early onset familial AD (FAD) or later onset “sporadic” AD. In
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familial AD (FAD), the less common of the two, autosomal genetic mutations directly
cause the disease. This form of AD accounts for 1-5% of the total cases of AD (Demattos
et al., 2000). Most of these cases occur before the age of 60, which is why it is often
called early-onset FAD. FAD is caused by inheriting abnormal variations of the amyloid
precursor protein (APP) gene, the presenilin 1 (PSEN1) gene, and/or the presenilin 2
(PSEN2) gene.
In the more common sporadic/late-onset form of AD, genes influence the risk of
developing the disease rather than directly causing the disease. Sporadic AD usually
occurs after the age of 60, which is why it is often called late-onset sporadic AD. The
most-studied gene of susceptibility in sporadic AD is the apolipoprotein E (APOE) gene.
As shown in Table 1, other genes, including α2M, LRP, ACE, and VLDL-R, can also
influence susceptibility to sporadic AD (Rocchi, Pellegrini, Siciliano, & Murri, 2003).

Table 1. Genes involved in familial (bold) and sporadic AD.
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Genetic Risk Factors
APP
The inheritance of mutated APP is a risk factor for FAD. Certain mutations in
APP result in the development of higher than normal levels of Aβ, leading to the
accumulation of Aβ plaques. This eventually causes neuronal dysfunction in the brain.
The processing of APP to Aβ occurs in normal individuals as well as those with AD, so it
is presumed that the development of AD is due to a mutation in this gene, which leads to
a change in either the quantity or quality of Aβ (LaFerla et al., 1996). These mutations
are a relatively rare cause of AD (Schellenberg, 1995). Since APP is located on
chromosome 21 and Down syndrome is caused by trisomy 21 (3 copies of chromosome
21), those with Down syndrome are more likely to developing AD.

Presenilin 1 and 2
Once APP mutations were found, extensive research suggested that these
mutations accounted for only a small subset of AD cases. Genetic linkage analysis led to
the identification of a chromosome 14 early-onset AD locus (Schellenberg, 1995)
Presenilins are a family of transmembrane proteins that act as a γ-secretase (an enzyme
that cleaves transmembrane proteins at residues within the transmembrane domain). The
presenilin 1 (PSEN1) gene and presenilin 2 (PSEN2) gene have been identified as a cause
of FAD (Schellenberg, 1995). Mutations in these genes are thought to cause up to 80% of
FAD cases (Rocchi et al., 2003).
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APOE
APOE is a gene located on chromosome 19 that has been shown to play a factor in
the pathogenesis of late-onset AD. APOE has three major alleles: APOE2 (E2), APOE3
(E3), and APOE4 (E4). These alleles produce the isoproteins apolipoprotein E2 (apoE2),
apoE3, and apoE4, respectively (Eto et al., 1986). The likelihood of one developing AD
is highly dependent upon which of these three alleles they carry (Corder et al., 1993).
ApoE is a ligand for the low-density lipoprotein receptor (LDLR), which is involved in
maintaining cholesterol and triglyceride homeostasis (Sullivan et al., 1997). A lipoprotein
is a group of soluble proteins that transports fats or lipids to the blood plasma. A lowdensity lipoprotein (LDL) carries cholesterol throughout the body and delivers it to
different organs and tissues. LDL is also considered the “bad” cholesterol since it
contributes to plaques. High-density lipoprotein (HDL) picks up excess cholesterol in the
blood and takes it back to the liver where it is broken down. It is considered as “good”
cholesterol since it helps remove LDL cholesterol from the arteries.
After the liver, the brain expresses the highest expression of apoE, particularly in
areas involved in neural development, regeneration, and remodeling (Grootendorst et al.,
2005; Kim, Basak, & Holtzman, 2009). The liver synthesizes about 70% of apoE in the
body, and the brain synthesizes about 20% (Sullivan et al., 1997). Similar levels of apoE
mRNA have been found in the cerebellum, medulla, and cerebral cortex of the rat brain
(Elshourbagy, Liao, Mahley, & Taylor, 1985). Besides the liver and the brain, apoE is
also synthesized in the spleen, lungs, adrenal glands, kidneys, and muscles (Blue,
Williams, Zucker, Khan, & Blum, 1983; Tokuda et al., 2000). Major cell types that
express apoE in the brain include astrocytes and microglia (Kim et al., 2009). ApoE has
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shown to play a role in the brain’s response to injury (Poirier, 1996; Tokuda et al., 2000).
Following injury, astrocytes and macrophages (cells that function in phagocytosis)
synthesize and release apoE within the lesion to repair the nervous system through
membrane synthesis (Poirier, 1996; Tokuda et al., 2000).
Corder et al. (1993) studied the genotype of 42 late-onset families that were
diagnosed with AD. Each individual has two APOE genes on chromosome 19. One copy
is inherited from each parent. With increasing numbers of E4 alleles, they found that the
risk for AD increased from 20% to 90%, and the mean age of onset decreased from 84 to
68 years. Compared to individuals lacking E4, those with one E4 allele are 2 to 3 times
more likely to get AD, and those with two E4 alleles are about 12 times more likely to get
AD (Bertram, McQueen, Mullin, Blacker, & Tanzi, 2007). The E4 allele is known to
increase the risk and decrease the age of onset of AD, whereas the E2 allele is known to
decrease the risk and increase the age of onset of AD. The E4 allele represents a major
risk for AD in a variety of ethnic groups (Farrer et al., 1997). A pilot study has found a
protective role in the E4 allele in the cognitive development in children with heavy
diarrhea in Northeast Brazil (Oriá et al., 2005).
The E3 allele encodes for the most common isoform and acts as a neutral allele,
not modifying the risk of developing the disease. From a normal representative United
States sample with a similar number of young and elderly males and females (n = 1209;
age range 22-71 years), the major APOE alleles, E2, E3, and E4, occurred at frequencies
of 7.5, 78.6, and 13.5%, respectively (Ordovas et al., 1987). Other rare isoforms (E1, E5,
and E7) have been reported (Weisgraber, Rail, Innerarity, & Mahley, 1984; Yamamura,
Yamamoto, & Sumiyoshi, 1984). The E1 and E5 alleles were found to occur at
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frequencies of 0.2% each (Ordovas et al., 1987). Hallman et al. (1991) found no evidence
that the effects of apoE polymorphism on plasma cholesterol levels were significantly
different among the nine populations studied; Tyrolean, Sudanese, Indian, Chinese,
Japanese, Hungarian, Icelandic, Finnish, and Malay. The frequencies did vary by
population though. The Chinese and Japanese appeared to show higher frequencies of ε3
and lower frequencies of ε4 than did the other populations. The high frequency of ε3 in
both populations has been reported in previous studies (Asakawa, Takahashi, Rosenblum,
& Neel, 1985; Eto et al., 1986; Tsuchiya et al., 1985).
The three alleles differ in their affinity for the LDLR. ApoE3 and apoE4 have a
100% binding affinity to LDLR (leading to an increase in LDL cholesterol), while apoE2
only has 1% normal binding affinity (leading to a decrease in LDL cholesterol; Sullivan
et al., 1997). Despite the lowing binding affinity of apoE2 for the LDLR, individuals
homozygous for ε2 usually have lower than normal plasma cholesterol levels, except for
the fraction of homozygotes (5-10%) who develop type III hyperlipoproteinemia
(Utermann, 1982).
Schmechel et al. (1993) selected autopsy-confirmed cases of late-onset AD
without affected family members and without other neurological disease as subjects for
their study. They found that the average neuritic plaque counts increased with two, as
opposed to one, copy of E4, and that the number of neuritic plaques was greater in the E4
than in the E4 homozygotes. To further investigate this trend, Schmechel et al. (1993)
looked at the impact that E3 and E4 alleles had on Aβ plaques in brain tissue sections.
They reported that homozygotes for E4 had a 5- to 7-fold greater average area covered by
strongly Aβ plaques compared to E3 homozygotes. Additionally, they found that there
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was a significant dose-related increase of vascular amyloid with the number of E4 alleles.
No vascular amyloid was observed in most of E3/3 cases, some vascular amyloid was
observed in E3/4 cases, and large amounts were reported for E4/4 cases (Schmechel et al.,
1993).
Previous research using in vitro models report that E4 enhances Aβ production
whereas E3 does so to a lesser extent (Mahley, Weisgraber, & Huang, 2006; Ye et al.,
2005). Ye et al. (2005) applies these findings to some in vivo findings to explain why E4
is associated with greater Aβ deposition than E3 in AD brains and in transgenic mice
expressing mutant APP. Various mouse models suggest how apoE4 can lead to the
development of Aβ deposits (Bales et al., 1999; Ye et al., 2005). As described by Games
et al. (1995), the development of Aβ plaques is derived from an accumulation of these Aβ
deposits, supporting the hypothesis that apoE4 mice will have more AD-like pathology
than apoE3 mice.

Others
As mentioned earlier, other genes involved in AD include α2M, LRP, ACE, and
VLDL-R (Rocchi et al., 2003). Α2-Macroglobulin (α2M) is a serine protease inhibitor, or
a protein that inhibits the breakdown of other proteins, that is expressed in the brain and
found in neuritic plaques (Dodel et al., 2000). The α2M gene is located on chromosome
12p. A genetic linkage was detected in late-onset families for a susceptibility gene on
chromosome 12 (Pericak-vance et al., 1997), which is why α2M became a candidate as a
disease locus for FAD. α2M plays a role in mediating the clearance and degradation of
Aβ (Blacker et al., 1998). Blacker et al. (1998) reported an association between a deletion
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in exon 18 of α2M and AD in a sample of affected and unaffected siblings segregating
AD. His study confirmed the risk of AD (OR=3.55) comparable to that of ε4 (OR=3.54).
However, studies using worldwide populations as samples failed to confirm such an
association (Dow et al., 1999; Rogaeva et al., 1999). For that reason, the possibility exists
that this α2M deletion could be a risk factor for FAD only (Rocchi et al., 2003).
The LRP gene (low density lipoprotein receptor-related protein) is another
candidate for a potential association with AD. LRP is the main apoE receptor expressed
in neurons (Rebeck, Reiter, Strickland, Hyman, & Cross, 1993), is responsible for the
endocytosis (the process of cells absorbing molecules by engulfing them) of secreted
APP (Kounnas et al., 1995), and is detected in senile plaques (general term for Aβ
plaques in the elder population), dystrophic neurites and reactive astrocytes in the AD
brain (Rebeck, Harr, Strickland, & Hyman, 1995). Multiple studies have shown that
certain polymorphisms in LRP may play as a minor risk factor for sporadic AD (Kamboh,
Ferrell, & DeKosky, 1998; Kang et al., 1997; Lendon et al., 1997).
The ACE gene (angiotensin converting enzyme) encodes for an enzyme that
catalyzes the conversion of angiotensin I to angiotensin II (Rocchi et al., 2003), a protein
that causes vasoconstriction. A polymorphism in ACE has been found to be associated
with AD susceptibility (Kehoe et al., 1999). Subsequent studies confirmed that certain
polymorphisms in ACE lead to an increased risk in late-onset AD (Alvarez et al., 1999)
including in Chinese (Cheng, Hong, Liu, Liu, & Tsai, 2002) and Japanese (Hu et al.,
1999) populations.
The VLDL-R gene (very low density lipoprotein receptor) is located on
chromosome 9. VLDL-R has shown to be found on microglia, particularly those
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associated with senile plaques (Christie, Chung, Rebeck, Strickland, & Hyman, 1996). A
number of genetic studies have investigated the effect that a polymorphic trinucleotide
(CGG) repeat sequence of VLDL-R, with alleles ranging from four to nine repeats, will
have on the risk for AD. A study investigating the Japanese population homozygous for
the five repeats allele leads to an increased risk for AD (Okuizumi et al., 1995). Contrary
to that study, there were no significant differences between AD cases and controls in
allele frequencies of the CGG repeat polymorphism in the Caucasian population
(Okuizumi et al., 1996). A case study was then done investigating these effects in lateonset AD patients from Northern Ireland (McIlroy et al., 1999). Findings suggested
carriers of 9,9 genotype of VLDL-R are at increased risk of AD in Northern Ireland.
Although the genetic studies from distinct populations on the CGG repeat polymorphism
in the 5’-untranslated region of VLDL-R obtained inconsistent results, the possibility of
VLDL-R acting as a susceptibility gene for AD exists.

Animal Models
Natural AD Development
Before the development of molecular genetics, the study of genes and pathology
was limited to inherited characteristics or spontaneous mutations. Selective breeding was
a common method that was used. Natural AD development has been studied in chickens,
dogs, non-human primates, dolphins, bears, guinea pigs, and rabbits because of their
highly homologous Aβ sequence to that of humans. Rats and mice, on the other hand,
have a distinct Aβ sequence from humans that does not naturally aggregate into a β-sheet
conformation. Chickens, dogs, non-human primates, dolphins, and bears have shown age-
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related human-like AD neuropathology, whereas, despite their homologous Aβ sequence
to that of humans, guinea pigs, and rabbits did not.
Carradeguas et al. (2005) revealed that the sequence of chicken APP is very
similar to the human sequence of APP. They also reported that the chick embryo
processes APP by both amyloidogenic (cleavage by β- and γ-secretases, leading to the
formation of Aβ plaques) and non-amyloidogenic (cleavage by α-secretase, preventing
the formation of Aβ plaques) pathways. In addition to the chicken Aβ sequence’s
similarity to that of humans, they also reported that Aβ42 was the major Aβ peptide
produced during chick embryogenesis (the formation and development of an embryo),
suggesting that the chick embryo may be appropriate for studying the mechanisms of Aβ
production.
Age-related Aβ deposition was reported in the prefrontal, occipital, parietal, and
entorhinal cortices of 40 beagle dogs ranging from 2 to 18 years of age (Head, McCleary,
Hahn, Milgram, & Cotman, 2000). Head et al. (2000) also found that the earliest and
most consistent site of Aβ deposition with age was in the prefrontal cortex, similar to
what is seen in the aging human. It has also been reported that the extent of the Aβ is
correlated with learning and memory impairments in aging dogs (Cummings, Head,
Afagh, Milgram, & Cotman, 1996a; Cummings, Head, Ruehl, Milgram, & Cotman,
1996b).
Natural models of non-human primates, dolphins, and bears have been studied as
well (Cork et al., 1988; Sarasa & Pesini, 2009). Unlike wild-type mice, many non-human
primates naturally develop Aβ plaques (Lemere et al., 2008). Lemere et al. (2008) found
age-related plaque deposition in tamarins older than 12 years of age. Also, tissue samples
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from stranded dolphins were found to have extensive positive Aβ-immunolabeled
deposits throughout the brain, including the cerebellum and medulla oblongata where
such deposits have only been reported in more severe cases of AD (Luo et al., 2001). The
Aβ42 peptide in three dolphin species was found to be 100% identical to the human
peptide (Sarasa & Pesini, 2009). Furthermore, two different types of bears have also
shown age-related human-like AD pathology (Cork et al., 1988). A 20-30 year old
Asiatic brown bear and polar bear displayed NFTs and numerous senile plaques,
respectively (Cork et al., 1988).
Although the Aβ sequence in guinea pigs and rabbits happen to be identical to
that of human (Johnstone, Chaney, & Norris, 1991), Sarasa and Pesini (2009) reported
that these animals did not present AD pathology spontaneously. Guinea pigs did not
develop the pathological features of AD, such as senile plaques and neurofibrillary
tangles. Although rabbits did not present AD pathology spontaneously, Wu et al. (2003)
reported that increased dietary cholesterol levels in rabbits led to increased Aβ and apoE
concentrations in the temporal and frontal cortices, regions where amyloid deposits have
been displayed in the pathology of AD.
Perhaps other factors, aside from the similar Aβ sequence to that of humans, may
describe the possible mechanism for why guinea pigs and rabbits do not develop agedependent AD-like neuropathology. The natural development of amyloid deposits may be
closely linked with the concentrations of β- and γ- secretase in the brain or a specific diet
that these animals generally have.
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Non-Transgenic Models
Before transgenic animals models became popular, non-transgenic animal models
were used. In these cases, the genetic material of the animal was not altered. Examples
consisted of injecting the Aβ40 peptide into rat brains via intrahippocampal injection
(Stéphan, Laroche, & Davis, 2001) or the Aβ42 peptide via intracerebroventricular
infusion (Lecanu, Greeson, & Papadopoulos, 2006; Nakamura, Murayama, Noshita,
Annoura, & Ohno, 2001). The overall goal in these studies was to inject a form of
amyloid peptide into the rat brain so that the animal would develop the pathological
features representative of AD. Alternative non-transgenic animal models include
streptozotocin injections (Y. Chen et al., 2013), okadaic acid-induced tau protein
hyperphosphorylation (Y.-W. Lim et al., 2010), and aluminum salt administration (Aly,
Metwally, & Ahmed, 2011). Also, a study from our group, in which a controlled cortical
impact (CCI) injury was administered to the parietal cortex of male rats at postnatal day
17, reported higher levels of endogenous rodent Aβ in several brain regions (Pop et al.,
2012). These findings suggest that juvenile traumatic brain injury (jTBI) animals may be
used an effective non-transgenic model for AD.

Transgenic/Knockout Models
The term “transgenic” refers to the artificial introduction of genetic material from
one organism to another. The first genetically modified animal was created in 1974, by
Rudolf Jaenisch (Jaenisch & Mintz, 1974). He had inserted a DNA virus into an earlystage mouse embryo and showed that that inserted gene was present in every cell, but the
transgene (the gene that has been transferred from one organism to another) was not
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passed to their offspring. In 1981, transgenic mouse models had successfully shown
transmission of genetic material to subsequent generations (Brinster et al., 1981;
Constantini & Lacy, 1981; Gordon & Ruddle, 1981). Gordon and Ruddle (1981) used
one of today’s most common methods for generating transgenic mice, DNA
microinjection. This method consists of injecting a single gene or a combination of genes
from one organism to another. This insertion of DNA is a random process, and there is no
way to ensure that the DNA will insert itself into a site on the host DNA that will permit
its expression.
Another method of generating transgenic mice is by way of embryonic stem cellmediated gene transfer. The first recorded KO mouse was in 1989 (Capecchi, 1989). This
method consists of inserting mutant embryonic stem (ES) cells, which are
undifferentiated cells that still have the potential to differentiate into any type of cell
(somatic and germ cells), into blastocysts in an embryo. This allows for the insertion of a
certain gene in a specific location of the researcher’s choice.

APP Models
Mutations
Prior to the development of PDAPP mice, animals transgenic for APP had failed
to show extensive AD-like neuropathology (Lamb et al., 1993; Quon et al., 1991). Quon
et al. (1991) generated transgenic mice that expressed APP-751, an isoform of APP.
These mice exhibited poorly resolved extracellular Aβ deposits in the hippocampus and
cortex. Lamb et al. (1993) introduced APP into mouse embryonic stem cells, which
showed no evidence of AD-type pathology.
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Once FAD-associated mutations in APP had been discovered, the focus of making
AD transgenic mouse models turned to including the overexpression of transgenes
containing FAD mutations (Elder et al., 2010). Games et al. (1995) created the first
successful AD transgenic mouse model that contained an FAD-associated mutation. The
resulting high level of human mutant APP in the brains of these mice resembled that of
early-onset FAD. This model consists of a human APP minigene, or a segment of APP
that codes for a portion of the APP protein, with a mutation that causes FAD (APPV717F).
The nomenclature of the mutation suggests that the valine amino acid (V) gets replaced
with the phenylalanine amino acid (F) at residue 717 along the APP peptide. The FAD
mutation at residue 717 shifts the production of Aβ from the 40-amino-acid form to the
longer and more amyloidogenic 42-residue peptide known to predominate in plaques ( a.
E. Roher et al., 1996; Suzuki et al., 1994). It is also highly expressed in the central
nervous system (Elder et al., 2010). This line became known as PDAPP (Platelet-Derived
growth factor promoter driving Amyloid Precursor Protein; Elder et al., 2010). In the
PDAPP transgenic mouse model, mice express high levels of human mutant APP,
causing neuropathology resembling that of early-onset FAD. This causes the mice to
progressively develop many of the pathological hallmarks of AD (Games et al., 1995),
such as age-dependent amyloid deposition in the brain, along with thioflavin-S-positive
plaques (Elder et al., 2010). PDAPP mice also developed age-related learning defects
(Richard E Hartman et al., 2005) and synapse loss (Elder et al., 2010). The first PDAPP
line generated showed no obvious pathology before about 6 months of age (Games et al.,
1995). At about 6-9 months of age, these transgenic mice showed Aβ deposits in the
hippocampus, corpus callosum, and cerebral cortex.
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Another line of transgenic mouse created from FAD-associated mutations is the
Tg2576 mouse (Elder et al., 2010). These mice, also known as APPsw, overexpress a
human APP transgene containing the Swedish FAD mutation (K670N/M67IL). This is a
double mutation where lysine (K) is replaced with asparagine (N) at residue 670, and
methionine (M) is replaced with leucine (L) at residue 671. These mice exhibited learning
and memory impairments by 9 to 10 months of age with a resulting a five-fold increase in
Aβ40 and a 14-fold increase in Aβ42 accompanying these behavioral deficits (Hsiao et al.,
1996). Considering how Aβ42 aggregates more rapidly and is more toxic to the neuron
compared to Aβ40 (Yan & Wang, 2006), these findings suggest the harmful effects of this
mutation. PDAPP mice (Fryer et al., 2003) generally have a lower ratio of Aβ40:Aβ42
compared to Tg2576 mice (Hsiao et al., 1996; Johnson-Wood et al., 1997). Other
transgenic AD mouse lines with FAD-type mutations include APP23, TgCRND8, APPDutch, PS1M146V, PSAPP, and 3xTg (Elder et al., 2010; Table 2).
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Table 2. Selected examples of AD mouse models.

APOE Models
Knockout
KO mice are defined as mice whose DNA has been genetically engineered so that
it does not express particular proteins. In the current study, that particular protein is apoE.
ApoE KO mouse models have been used to investigate the role of apoE in the nervous
system. Fagan et al. (1998) found no significant defects in the septo-hippocampal
cholinergic system (plays a role in spatial working memory) in aged apoE KO mice (up
to 24 months of age). Hartman et al. (2001) found that mice lacking apoE were
significantly more active than wild-type mice. Also, Shibata et al. (2000) found that,
compared to adult wild-type mice, Aβ clearance was significantly reduced in young and
old apoE KO mice.
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Human APOE
Other studies investigated the role of human APOE in the AD brain by using
human apoE KI mouse models. Sullivan et al. (1997) used a gene replacement strategy to
generate mice that express human E3 in place of murine APOE. Although murine APOE
is about 70% identical to human APOE at the amino acid level, there are inherent
functional differences between murine and human APOE isoforms on plasma lipoprotein
metabolism in vivo (Sullivan et al., 1997). He found that after the 3/3 (E3 KI) and WT
mice were fed a high fat/high cholesterol diet, the 3/3 mice responded with an increase in
cholesterol 5 times to that of the WT mice. After 12 weeks of being on the diet, the 3/3
mice also developed 13-fold larger atherosclerotic plaques in the aortic sinus area than
the WT mice. In contrast to murine APOE, human APOE isoforms have been known to
suppress early Aβ deposition and Aβ levels in 9-month-old PDAPP mice (D M Holtzman
et al., 2000; David M Holtzman et al., 1999).
Yao et al. (2004) compared Aβ accumulation among human E3 KI, human E4 KI,
and murine APOE KO mice. They found that E4 carriers had higher levels of Aβ than
either E3 or APOE KO mice. Aged male E4 mice appeared to have the highest average
values for Aβ40, Aβ42, and total Aβ (Yao et al., 2004). Grootendorst et al. (2005) was the
first study to investigate and compare the behavioral phenotype of KI human E3 and E4.
He found that spatial memory deficits occurred particularly in human E4 mice, especially
female.

APP x APOE Models
Once APOE KO mouse models had led to a more clear understanding of the apoE
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protein, APOE KO mice were crossed with PDAPP mice. Bales et al. (1999) found that
the amount of Aβ immunoreactivity in the hippocampus of transgenic mice
overexpressing the V717F human APP with no, one, or two APOE alleles was
dramatically reduced in an APOE dose-dependent manner (APOE+/+ > APOE+/- >>
APOE-/-). Bales et al. (2009) further investigated the role of human APOE on Aβ
deposition by crossing PDAPP mice lacking murine APOE to targeted replacement mice
expressing human E4 (PDAPP/TRE4). They found that the brain levels of Aβ42 in
PDAPP/TRE4 mice were significantly elevated in young mice.
Hartman et al. (2002) investigated these effects in a PDAPP x APOE model
having undergone traumatic brain injury (TBI). They found that TBI accelerated Aβ
deposition, such that PDAPP mice expressing E4 displayed Aβ deposition by 12-13
months of age in the presence of TBI compared to about 15 months of age in the absence
of TBI. They also found a greater and earlier amyloid deposition in PDAPP:E4 mice than
in PDAPP:E3 mice in the presence of TBI.

Humans with AD
Studies on humans with AD have assessed the differences in neuropathological
and behavioral deficits between those who are carriers of the E4 allele versus those who
are carriers of the E3 allele. In a study assessing 194 AD cases and 3,984 cognitively
normal controls, findings indicated E4 was significantly associated with an increased risk
of AD compared to E3 (Lindsay, J., Laurin, D., Verreault, R., Hebert, R., Helliwell, B.,
Hill, G. B., McDowell, 2002). Specifically, those who had at least one E4 allele had 3.28
times the risk of AD compared to those who were homozygous for the E3 allele.
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In terms of neuropathological deficits, the apoE isoform 4, which is the protein
encoded by the E4 allele, has a higher avidity in vitro for β-amyloid than the apoE
isoform 3 (Corder et al., 1993). This study found that E4 increases the rate and extent of
amyloid deposition compared to the E3 allele. Another study (Schmechel et al., 1993),
found that late-onset AD patients with one or two E4 alleles have a distinct
neuropathological phenotype compared with patients homozygous for the E3 allele.
Specifically, AD patients homozygous for the E4 allele had abundant immunoreactive
plaques whereas AD patients homozygous for the E3 allele only had slight
immunoreactive plaques. These differences were so evident that they were often observed
without a microscope. AD patients homozygous for the E4 allele also had more neuritic
plaques and NFTs in the CA1 subfield of the hippocampus and cortical regions compared
to those homozygous for the E3 allele. In another study, E4:E3 AD patients also had
lower cortical thickness values compared to those homozygous for the E3 allele in
regions associated with early pathological changes in AD (CA1 subfield of the
hippocampus and parietal regions).
In terms of behavioral changes, Bookheimer et al. 2000 found that AD patients
who were carriers of the E4 allele had lower scores on a delayed-recall test, although not
significantly lower, than did carriers of the E3 allele. They also found significant
increases in the functional magnetic resonance imaging (fMRI) signal intensity during
learning and recall periods as compared with resting periods. This intensity was greater
among the carriers of the E4 allele compared to carriers of the E3 allele, which was later
correlated with degree of decline in memory in a longitudinal assessment after two years.
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These findings suggested that subjects at genetic risk for AD used greater cognitive effort
to achieve the same level of performance as subjects who were not at genetic risk.

Thesis
The double-transgenic mice used for the current study were obtained from the Eli
Lilly Corporation in 2009, where they crossbred PDAPP transgenic mice with apoE KO
mice. This KO technology consisted of removing the murine APOE from their genomes
and, via KI technology, replacing it with a human variation of E3 or E4 in the precise
location within the mouse genome that the murine APOE was removed from. Given the
similarities in behavior and neuropathology between humans with AD and transgenic
mouse models for AD, transgenic mouse models for AD have frequently been used to
gain a better understanding of the disease and to characterize the neuropathological
mechanisms.

Hypothesis One
The first hypothesis states that PDAPP:E4 mice will show more Alzheimer’s-like
pathology in the hippocampus and dorsal cortex than the PDAPP:E3 mice. The
hippocampus and cingulate cortex showed dramatic age-related increase in Aβ levels in
PDAPP mice (Johnson-Wood et al., 1997) and in mice that co-express five FAD
mutations (Oakley et al., 2006). The hippocampus also showed significantly more Aβ
load in old PDAPP mice compared to young or middle-aged PDAPP mice (Games et al.,
1995) and in PDAPP mice of all ages compared to controls (Demattos et al., 2000).
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A study was done to assess the amount of amyloid deposition, which is a main
component of Aβ plaques, in three different mouse genotypes of one particular mouse
model overexpressing APPV717F (PDAPP; Bales et al., 1999). Mice that were
homozygous (carrying two identical alleles of a particular gene) for the APPV717F
transgene were crossed to an APOE KO mouse. The resulting hemizygous progeny were
subsequently bred, and the following genotypes were selected for the study: APPV717F+/:APOE-/- (1 copy of the human APPV717F; 0 copies of murine APOE), APPV717F+/-:APOE+/(1 copy of the human APPV717F; 1 copy of murine APOE), and APPV717F+/-:APOE+/+(1
copy of the human APPV717F; 2 copies of murine APOE). The results suggested that in the
case of the APPV717F+/- APOE-/- mice, where the mice were APOE-deficient, no amyloid
deposits were formed at 9, 15, or 21-22 months. When mouse APOE was present (as with
the APPV717F+/-:APOE+/- and APPV717F+/-:APOE+/+ mice), the researchers found an agerelated increase of amyloid deposits in the hippocampus and the cortex. These results
suggest that amyloid deposits develop in cases where APOE is present, but not when
APOE is absent. Although these mice expressed mouse (murine) APOE rather than
human APOE, the findings emphasize the critical role that APOE plays in amyloid
deposition, especially when there is an overexpression of mutant APP.
Johnson-Wood et al. (1997) measured the total Aβ and APP measurements in
PDAPP mice from 4 to 18 months of age. A total Aβ sandwich ELISA (enzyme-linked
immunosorbent assay), a test using antibodies and color change to detect a sample
antigen by “sandwiching” the antigen in between the two antibodies, was conducted. This
test used antibodies 266 and 3D6, which are specific to certain amino acid epitopes

29

within the Aβ peptide. The Aβ levels appeared to increase significantly by age in the
hippocampus (Figure 2).

Figure 2. The age-dependent changes in brain Aβ levels in the PDAPP transgenic mice
in the hippocampus (white circle), cortex (white diamond), and cerebellum (black square).
PDAPP mice were sacrificed at the ages indicated. The Aβ levels increased significantly
by age in the hippocampus compared to the other cortex and cerebellum (Johnson-Wood
et al., 1997).

There was also an age-related increase in Aβ in the hippocampus of PDAPP mice due to
Aβ42. Aβ42 comprised of 27% of the 17 pmol/g of Aβ present in the brains of young
animals and increased to 89% of the 694 pmol/g in the 12-month-old animals. Between
12 and 16 months of age, an even more dramatic increase in deposition of Aβ occurred in
the hippocampus and frontal region of the cortex. By 18 months, Aβ42 levels in the
PDAPP mice were comparable to the higher Aβ levels observed in humans with AD
(Gravina et al., 1995). Initially, before amyloidotic deposition, there were 38.1 pmol/g of
Aβ in the hippocampus of these young animals. The model used by Johnson-Wood et al.
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(1997) is an accurate representation of human AD pathology such that the majority of
depositing Aβs in these mice were in the longer Aβ42 form, and studies of human AD
have shown that the predominant and initially depositing Aβs are the longer form.
APP/PS1 double transgenic mice overproduce Aβ42 and exhibit plaque pathology,
but transgenic mice develop plaques slowly. The majority of AD transgenic mouse
models take about 6-12 months, or longer, to form amyloid plaques (Oakley et al., 2006).
To accelerate plaque development, Oakley et al. (2006) investigated APP/PS1 double
transgenic mice that co-express five FAD mutations (5XFAD mice) to investigate the
effects of high Aβ42 levels. The five FAD mutations were APP K670N/M671L (Tg2576
mice previously described), APP I716V (isoleucine is replaced with valine at residue 716
on the APP peptide), APP V717I (valine is replaced with isoleucine at residue 717 on the
APP peptide), PS1 M146L (methionine is replaced with leucine at residue 146 on the PS1
peptide), and PS1 L286V (leucine is replaced with valine at residue 286 on the PS1
peptide). These mutations were introduced into the cDNA (complimentary DNA) by sitedirected mutagenesis. They found that intraneuronal Aβ42 accumulated at 1.5 months of
age, before the first appearance of Aβ deposits at 2 months. There was a rapid increase of
cerebral Aβ42 levels in 5XFAD mice (Oakley et al., 2006). At young ages, these mice
generated Aβ42 levels almost exclusively (Figure 3). Aβ40 levels began to rise at older
ages, although always lower than Aβ42 levels (Figure 3).
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Figure 3. The rapid increase of cerebral Aβ42 levels in 5XFAD lines from 1.5 to 16month-old 5XFAD mice (A. Tg6799; B. Tg7092; C. Tg7031; D. Tg2576). (Oakley et al.,
2006).
In a study of confirmed cases of AD, in which autopsies were performed within 8
hours from death, those who were homozygous for the E4 allele had increased neuritic
plaques compared with patients with no E4 alleles. This suggests a positive correlation

32

between plaque density and E4 allele dose (Tiraboschi et al., 2004). It is believed that the
physical interaction of APOE with Aβ plays an important role in AD pathogenesis.
It is the specific effect that E3 and -4 have on the human Alzheimer’s brain that
are of interest in the current study. The binding affinity of E4 with Aβ is high and has
significantly different binding characteristics compared to that of E3 (Schmechel et al.,
1993). Schmechel et al. (1993) looked at the relationship that E3 and -4, the two most
common alleles of the APOE gene, have on Aβ deposition in late-onset AD, since E4 is a
susceptibility gene for late-onset AD. They found that patients with sporadic late-onset
AD who have one or two copies of E4 have a distinctive neuropathological phenotype of
greatly increased vascular and plaque amyloid deposits compared to patients homozygous
for E3.
As mentioned earlier, in selected autopsy-confirmed cases of late-onset AD,
Schmechel et al. (1993) found more Alzheimer’s-like pathology (neuritic plaques, Aβ
plaques, and vascular amyloid) in E4 homozygotes than E3 homozygotes. Several other
studies, as mentioned earlier, have reported that E4 enhances Aβ production while E3
does so to a lesser extent (Kelly R. Bales et al., 1999; Mahley et al., 2006; Ye et al.,
2005). In one mouse model, highly relevant to the current study, Bales et al. (2009)
measured the levels of APOE protein and Aβ peptides in mice at different ages. The
mouse model consisted of crossing PDAPP mice lacking mouse APOE to targeted
replacement mice expressing human APOE. Findings suggested that there was an agedependent increase in both Aβ40 and Aβ42, regardless of APOE isoform analyzed, which
was more pronounced in the PDAPP/TRE4 mice. This study also did not administer any
behavioral tests on their mice, something that our study will be addressing. By running
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behavioral tests in our study, we are able to analyze any correlates between the
behavioral deficits and neuropathology seen in their brains. Having a clear understanding
of the impact that specific isoforms of APOE play in the development of AD can lead to
the development of preventive techniques as well as accurate prognoses of AD patients.

Hypothesis Two
The second hypothesis states that the PDAPP:E4 mice will have fewer cells in the
hippocampus and cortex than the PDAPP:E3 mice. The hippocampus, specifically the
CA1 hippocampal subfield (Figure 4), is known to have substantial neuronal loss in AD
patients (Mann, 1996; West, Coleman, Flood, & Troncoso, 1994) as well as in APP23
transgenic mice (Calhoun et al., 1998).

Figure 4. A sagittal view of a wild-type mouse brain. The CA1 hippocampal subfield is
known to have substantial neuronal loss in AD patients (Mann, 1996; West et al., 1994)
as well as in APP23 transgenic mice (Calhoun et al., 1998).
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Several studies of various transgenic mouse models of AD have also reported a lack of
cell loss in the CA1 hippocampal subfield (Irizarry et al., 1997; Jawhar et al., 2012;
Takeuchi et al., 2000). Although studies have shown both the presence and absence of
cell loss in various transgenic mouse strains, the phenomenon has yet to be studied in
PDAPP mice that also express human E3 or E4.
In one study (Friedrich et al., 2010), Aβ aggregation was induced in vitro by
adding dissolved Aβ40 to cultures of several cell types (human embryonic kidney cells,
neuroblastoma cells, laryngeal carcinoma cells, monocytic cells, simian kidney cells, and
a murine macrophage line). These cells lines are relevant to AD in that they all share the
ability to enable Aβ plaque formation. They found that plaque biogenesis involves Aβ
accumulation within intracellular vesicles, and the fibrils formed by Aβ in these
conditions impair the ordered vesicular formation by growing out and penetrating the
vesicular membrane. These events lead to the death of the affected cells and the
extracellular accumulation of previously intracellular amyloid structures (Friedrich et al.,
2010). The cell death reported in this cell-culture system is associated with plaque
biogenesis, not necessarily with the massive neuronal loss in AD patients. Duyckaerts et
al. (2007) found that transgenic mouse brains can have a lot of Aβ plaque despite very
little neuronal death, supporting the notion that cell death is not related to the massive
neuronal loss in AD patients.
In another in vitro study, the isoform-specific effects of APOE on the response of
Neuro-2a cells to the Aβ peptides were assessed. Neuro-2a is a mouse neural crestderived cell line, which is beneficial in the fact that they differentiate into neurons within
a few days. This allows for an efficient way of studying neurons. ApoE3- and E4-
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transfected Neuro-2a cells were incubated with 20 µM Aβ42 for 18 hours at 37ºC, and cell
survival was assessed. Transfection is a method of introducing nucleic acids into cells.
Findings suggest that Aβ42 caused significantly greater cell death in E4-secreting than in
E3-secreting or control cells (Ji et al., 2002). This provides evidence for the second
hypothesis that E4 leads to more cell death than E3 in the presence of Aβ.
Estus et al. (1997) found that treatment of cultured rat cortical neurons with Aβ40
results in a widespread of apoptotic neuronal death. Apoptosis refers to a regulated selfdestruction of cells whereas necrosis refers to cell death due to disease, injury, or failure
of the blood supply. Finally, Loo et al. (1993) studied cultured cortical and hippocampal
neurons from mouse embryos treated with Aβ42. They reported that these neurons
exhibited classical morphological and biochemical characteristics of apoptosis, which
they believe may play a role in the neuronal loss associated with AD. The concentration
Aβs used in these in vitro studies ranged from 5-40 µM.
In an in vivo study, LaFerla et al. (1996) found that their transgenic mouse model
(overexpression of the murine homologue of the Aβ peptide), consisting of intracellular
expression of Aβ specifically in neurons, led to the death of neurons as well as the
functional impairment of neighboring neurons. They found that the hippocampus of the
Aβ transgenic mice, among other areas in the cerebral cortex, was an area of apoptotic
cells. The observation that Aβ expression induces cell death through the apoptotic
pathway in vivo may prove relevant for therapeutic approaches to the treatment of AD.
Further transgenic studies have addressed the cell loss associated with APP and
PS mutations. In Schmitz et al. (2004), neuronal loss was observed in transgenic mice
expressing human mutant APP (APP751) and human mutant presenilin-1 (PS-1 M146L).
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This specific mutation in APP consists of the KM670/671NL and V717I mutations. They
found no hippocampal granule cell loss (cells located in the dentate gyrus of the
hippocampus) at 17 months of age in the APP/PS-1 double transgenic mice as compared
to age-matched PS-1 single-transgenic mice and wild-type controls. The neuron loss was
observed at sites of Aβ aggregation. The amount of extracellular Aβ aggregates in these
APP/PS-1 double transgenic mice increased as they aged, and they found a clear agerelated loss of neurons in the pyramidal cell layer of the hippocampus (Schmitz et al.,
2004). Specifically, they found a substantial loss of pyramidal neurons in the
hippocampus of 17-month-old APP/PS-1 double transgenic mice compared to 4.5-monthold APP/PS-1 double transgenic mice and wild-type controls. The neuronal loss was also
observed in areas of the parenchyma, the functional tissue in the brain, distant from
plaques. Also, they found no correlation between the number of pyramidal cells and
plaque load, which fell in line with a study reporting little or no correlation between the
level of neuron loss and the amount of extracellular Aβ in human AD (Gomez-isla et al.,
1997). This suggests the possible involvement of more than one mechanism of
hippocampal neuron loss in this double-transgenic mouse model of AD. Perhaps part of
the hippocampal neuron loss may be due to the high levels of intra-neuronal Aβ
independent of extracellular Aβ aggregates.
Another study had reported significant neuron loss in the hippocampal CA1
region in APP23 transgenic mice compared with controls, which was correlated with
CA1 plaque load in the transgenic mice within the hippocampus (Calhoun et al., 1998).
In this study, the CA1 neuron loss in the APP23 transgenic mice was 14% and had
reached 25% in mice with high plaque load (Calhoun et al., 1998). Other studies have
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failed to find CA1 hippocampal neuron loss in PDAPP transgenic mice through 18
months of age (Irizarry et al., 1997), PSAPP mice doubly expressing AD-associated
mutant presenilin-1 (PS-1) and APPsw (Takeuchi et al., 2000), and 5XFAD mice (Jawhar
et al., 2012). Jawhar et al. (2012) found significant pyramidal neuron loss in layer 5 of the
cortex, leaving the hippocampus of the 5XFAD mice completely unaffected (Oakley et
al., 2006).
A more severe hippocampal neuronal loss is seen a APP/PS1K1 mouse model
(Casas et al., 2004). The transgenic mouse model carries M233T/L235P (a double
mutation where methionine is replaced with threonine at residue 233 and leucine is
replaced with proline at residue 235) KI mutations in presenilin-1 and overexpresses
mutated human APP. At 10 months of age, these transgenic mice showed an extensive
neuron loss (>50%) in the hippocampus. The neuron loss was correlated with the
accumulation of intraneuronal Aβ and thioflavin-S-positive intracellular material.
As addressed by our first hypothesis, E4 leads to greater Aβ production than does
E3 in transgenic mice and humans (Kelly R. Bales et al., 1999, 2009; Mahley et al., 2006;
Schmechel et al., 1993; Tiraboschi et al., 2004; Ye et al., 2005). Previous studies have
also shown that Aβ aggregation induces neuronal cell death (Estus et al., 1997; LaFerla et
al., 1996; Loo et al., 1993). Intuitively, one would induce that E4 must lead to more
neuronal cellular death than E3, but research has shown no correlation between Aβ
deposition and neuronal loss (Gomez-isla et al., 1997; Schmitz et al., 2004). Although,
the pyramidal neuron loss in cortical layer 5 (Oakley et al., 2006) occurred in brain
regions with the highest levels of both intraneuronal Aβ accumulation and amyloid
plaque burden. In fact, the actual link between amyloid plaques and neuronal loss has yet
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to be established (Schmitz et al., 2004). The current study investigates neuronal loss in
the PDAPP x apoe3 vs. apoe4 model.

Hypothesis Three
The third hypothesis states that the Alzheimer’s-like pathology will be positively
correlated with the behavioral deficits displayed in the mice. In humans with AD,
cognitive and behavioral disturbances caused by the disease do not become evident until
years after significant neuropathology, which includes a large amount of plaques
accumulating and the occurrence of cell death (Morris & Price, 2001). Hartman et al.
(2005) reported that PDAPP mice had substantial learning impairments from early ages,
as well as an age-dependent decline in learning ability. Whereas both non-transgenic and
PDAPP mice showed evidence of decreased performance with age in the spatial learning
task, the performance of PDAPP mice declined much more severely. This suggests that
age-related Aβ buildup may have negative consequences for spatial learning. They then
treated the non-transgenic and PDAPP mice with anti-Aβ antibody 10D5, a reagent
specific for human Aβ, to determine whether this learning impairment was due to Aβ
accumulation. They found that aged PDAPP mice exhibited significant improvements in
the spatial learning task, suggesting that Aβ contributed to the age-dependent learning
deficits displayed in PDAPP mice, providing support for our third hypothesis. Similarly,
in another study in which spatial learning performance was tested in PDAPP and nontransgenic mice, a significant negative correlation between spatial learning capacity and
plaque burden existed for middle-aged and old PDAPP mice (G. Chen et al., 2000). They
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also found that PDAPP mice had a significant age-related increase of plaque burden in
the hippocampus.
The overall goal of the current study is to determine the roles that E3 and -4 play
in a PDAPP x APOE double transgenic mouse model. Understanding this role will
provide further insights into its pathophysiological role in AD. Also, these further
insights will lead to the development of more effective treatments and therapeutics for the
disease.

Successful Completion of Aims
Achievement of the first two aims will allow us to determine the effects of apoE
isoforms and overexpression of human mutant APP on AD-like pathology and cell count
within the hippocampus and dorsal cortex of transgenic mice that express human mutant
APP and human APOE. The third aim will allow us to determine the effects of the ADlike pathology, specifically Aβ plaques, on behavior, suggesting that reduction of Aβ
could be of potential therapeutic benefit for AD. By understanding where the plaque
deposition and cell loss is located, therapeutic benefits may target cognitive functioning
associated with those regions of the brain.
Achievement of these three aims will aid in a more formal understanding of the
precursors to this disease, specifically APP and APOE. This will give incentive in
developing more effective primary treatment and preventative interventions for AD. With
effective primary treatment developed, there will be more motivation for individuals to
get tested for their APP and APOE genes, allowing for an earlier detection of AD. This
will likely decrease the prevalence of AD. Determining whether Alzheimer’s pathology is
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correlated with behavioral deficits will improve technologies as well. Aside from
developing effective treatment, technologies will be developed to make living with AD
more manageable. By accepting the fact that behavioral deficits are inevitable, scientists
and researchers may develop effective computer programs that make those behavioral
deficits manageable in their day-to-day routine.
If the first and second hypotheses are supported, then the detrimental effects of E4
on the human brain may be accurately represented in this double transgenic KI mouse
model. Since those who are homozygous for E4 do not invariably develop AD, the exact
mechanism for how APOE alleles influence the risk of AD is still unclear (Kelly R. Bales
et al., 2009; Corder et al., 1993; Kim et al., 2009; Mahley et al., 2006). According to Kim
et al. (2009), strong evidence suggests that APOE influences the risk of AD via its effects
on Aβ metabolism. ApoE gets lipidated by ABCA1 to form lipoprotein particles. ABCA1
(ATP-binding cassette A1) transfers cellular cholesterol and phospholipids onto lipidpoor apolipoproteins to form pre-HDL. This lipidated apoE binds to soluble Aβ, which
influences the formation of parenchymal amyloid plaques and transport of Aβ within the
CNS. Hence, increasing the lipidation state of apoE may influence the Aβ metabolism in
the mouse brain or the ability of Aβ to form amyloid fibrils. It is believed that ABCA1
deletion increases Aβ deposition by affecting the lipidation state of apoE (Wahrle et al.,
2005). However, the details of this mechanism are not clearly understood (Kim et al.,
2009).
Strong evidence suggests that a major mechanism underlying the link between
apoE and AD is related to the interaction between apoE and Aβ and apoE’s ability to
influence Aβ’s clearance, aggregation, and conformation (D. Holtzman, 2004; Tokuda et
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al., 2000). Different apoE isoforms alter AD pathogenesis via their interactions with Aβ
peptide (Wahrle et al., 2005). The mechanism by which apoE interacts with Aβ is still not
clearly understood, but murine apoE has been found to somehow influence Aβ to a βpleated sheet conformation (K. R. Bales et al., 1997; Kelly R. Bales et al., 1999).
Holtzman (2004) investigated the effects of human apoE isoforms on Aβ deposition in
vivo. Holtzman (2004) found that although PDAPP+/- mice in the presence or absence of
murine apoE developed Aβ deposits by 9 months of age, PDAPP+/- mice with human E2,
3, and 4 did not develop Aβ deposition until 15-24 months of age. At 15 months of age,
the E3 and 4 mice developed Aβ deposition in the form of both diffuse and neuritic
plaques, similar to that seen in the presence of murine apoE. By 18-22 months of age,
some E2 mice had begun to develop diffuse plaques, but none had developed neuritic
plaques. This data suggests the isoform-specific role in the apoE-Aβ interaction.
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CHAPTER THREE
INNOVATION
The specific animal model used in the current study is distinct from previous
studies investigating PDAPP mice expressing human E3 and E4 in that they did not
assess behavior (Kelly R. Bales et al., 1999; Fagan et al., 2002; D M Holtzman et al.,
2000; David M Holtzman et al., 1999). Hartman et al. (2002) investigated PDAPP mice
expressing human E3 and E4 as well, with the addition of TBI. In analyzing the
neuropathology of AD in mouse brains, the current study addresses a novel way of
producing the double-transgenic mice, representing a “cleaner” double-transgenic mouse
model compared to what is normally seen in previous literature. In the current study,
APOE KO mice had human variations of E3 and E4 replaced via KI technology. KO
mice are mice whose DNA has been genetically engineered so it does not express a
certain protein. These human variations of APOE were placed in the exact location within
the mouse genome that the mouse APOE was removed from. Hypothetically, this resulted
in an Aβ and APOE interaction more similar to what is seen in humans with AD. These
mice were then crossbred with PDAPP transgenic mice. The advantage to using this
specific double-transgenic mouse model is that it leads to a more accurate representation
of the human Alzheimer’s brain.
Additionally, this current study measures the cognitive and behavioral deficits
resulting from this specific double-transgenic mouse model. Behavioral deficits have
been investigated in the past, but of transgenic animal models that were different from
what was used in the current study. Bales et al. (2009) had performed a study using a
similar mouse model to ours, but did not study behavior. The current study will not only
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assess the neuropathology of the disease brought about by the interaction of human
APOE and human mutant APP, but also the resulting behavioral deficits.
Previous research from our lab has characterized the neuropathological and
behavioral profiles of various transgenic mouse models. In one study, Hartman et al.
(2001) crossed APOE KO mice with transgenic mice expressing either human E3 or
human E4 to examine the effects of human APOE in the absence of endogenous murine
APOE. Compared to human APOE, murine APOE is most similar to E3 and 4, as shown
in Holtzman (2004) where E3 and 4 mice developed diffuse and neuritic plaques similar
to those seen in the presence of murine APOE.
PDAPP+/- mice in the presence or absence of murine APOE all began to develop Aβ
deposits by 9 months of age (D. Holtzman, 2004). Another study using an APP
transgenic mouse model of AD showed that the absence of murine APOE does not result
in a delay in the onset of Aβ deposition (David M Holtzman et al., 1999), but it does
result in a decrease in the level of Aβ deposition (K. R. Bales et al., 1997).
Hartman et al. (2001) was the first to report the behavioral phenotyping of GFAPE3 and GFAP-E4 transgenic mice in which both isoforms of human APOE are expressed
in glia. Glia is the predominant cell type in the CNS that synthesizes APOE in mammals.
The GFAP (glial fibrillary acidic protein) gene provides information for the GFAP
protein. This protein is an intermediate filament (cytoskeletal components, responsible
for cell shape, division, and function) that is expressed by numerous cell types of the
CNS including astrocytes (Jacque et al., 1978; Venkatesh et al., 2013).
Hartman et al. (2001) carried out a longitudinal study where E3 and E4 mice were
compared with APOE KO and WT mice (all male). Various behavioral measures were
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conducted. ApoE4 mice appeared to be the most “emotionally reactive” compared to E3,
APOE KO, and WT mice. ApoE4 mice were also significantly impaired on working
memory tasks. The presence of behavioral impairments and the lack of AD-like
neuropathology displayed in the E4 mice suggests that the APOE genotype plays a role in
the AD-related cognitive impairments in humans, which may be distinct from any effects
on Aβ structure and deposition.
Hartman et al. (2002) then looked at how APOE and TBI affect the development
of AD. The model consisted of PDAPP mice expressing human E3, E4, or no APOE
subjected to unilateral cortical impact injury. The TBI was induced at 9-10 months of age
and monitored for 3 months. It was previously found that PDAPP mice expressing human
ε3 and ε4 do not develop Aβ deposition until about 15 months of age (D M Holtzman et
al., 2000). Hartman et al. (2002) found that, following TBI, a high percentage of braininjured PDAPP:ε4 mice had Aβ deposition by 12-13 months of age. The TBI appeared to
accelerate Aβ deposition in the form of amyloid in the presence of human ε4 to a greater
extent than ε3 (Richard E Hartman et al., 2002). Also, they found that the PDAPP mice
that did not express human APOE had significantly greater Aβ load than those that
expressed ε3 and ε4. However, the Aβ deposits were non-fibrillar, consisting of only
thioflavin-S-negative Aβ (Richard E Hartman et al., 2002).
Thioflavin-S-positive Aβ was only present in the dentate gyrus in the PDAPP:ε4
mice, specifically 44% of the 56% of the Aβ-immunoreactive deposits (Richard E
Hartman et al., 2002). Thioflavin-S-positive Aβ suggests the presence of fibrillar amyloid
deposition. The dentate gyrus is located in the inner portion of the hippocampus, as
depicted by the letters “DG” in Figure 4. No PDAPP:ε3 mice had fibrillar amyloid
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deposition. There also existed no significant difference in the amount of brain tissue or
cell loss across the groups. Given that the presence or absence of APOE isoforms was the
only difference between the groups of PDAPP mice, they found that the isoform-specific
APOE-Aβ interactions contribute to the premature development of AD pathology
(Richard E Hartman et al., 2002).
In heterozygous PDAPP mice, Aβ deposition in the molecular layer of the dentate
gyrus was compared in mice expressing no APOE, murine APOE, or various isoforms of
human APOE (Fagan et al., 2002). Aβ deposition was the most robust in the molecular
layer of the dentate gyrus in animals expressing mouse APOE and increased with age
(Figure 5). PDAPP mice expressing E4 also displayed increases in Aβ deposition, but to
a much less magnitude than that observed in the murine APOE mice. The amount of Aβ
deposition in the dentate gyrus was low in the absence of APOE up to 18 months, but
increased by 21 months (Fagan et al., 2002).
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Figure 5. The Aβ deposition in the molecular layer of the dentate gyrus, in heterozygous
PDAPP mice, was compared in mice expressing no apoE, murine apoE, or various
isoforms of human apoE. PDAPP mice expressing apoE4 also displayed increases in Aβ
deposition, but to a much less magnitude than that observed in the murine apoE mice
(Fagan et al., 2002).
Hartman et al. (2002) differs from the current study in that a TBI is induced and
that the transgenic mice were not “targeted” replacement/KI mice. Also, they found no
significant difference in the amount of cell loss across groups (PDAPP:ε3, PDAPP:ε4,
PDAPP:ε-/-). This lack of difference may be due to the fact that the TBI may have had a
larger affect on the PDAPP:ε3 and PDAPP:ε-/- mice, diminishing the difference of cell
loss across groups. TBI was not induced in the current study, allowing us to investigate
the cellular loss solely based on the double transgenic mice, with no other interfering
variables.
Hartman et al. (2005) then characterized Aβ plaque load and learning deficits in
the PDAPP transgenic mouse model. They found that the PDAPP mice had a substantial
age-dependent decline in learning ability. To determine whether the age-related spatial
learning deficits were due to the Aβ accumulation, Hartman et al. (2005) treated WT and
PDAPP mice with a passive anti-Aβ antibody (10D5), which specifically targets Aβ by
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binding to amino acids 3-6 in the n-terminus (towards the beginning of the Aβ peptide)
(Hyman, Tanzi, Marzloff, Barbour, & Schenk, 1992). Over several weeks of treatment
with 10D5, aged PDAPP mice improved in hippocampal long-term potentiation and
behavioral performance with substantial Aβ burden. This suggests that Aβ had in fact
contributed to the age-dependent learning deficits displayed in PDAP mice. Should our
first hypothesis (PDAPP:E4 mice will show more Alzheimer’s-like pathology in the
hippocampus and dorsal cortex than the PDAPP:E3 mice) be correct, the findings from
Hartman et al. (2005) would aid in supporting the third hypothesis (Alzheimer’s-like
pathology will be positively correlated with the behavioral deficits displayed in the mice).
The advantage to using this mouse model over the aforementioned models is
establishing a baseline behavioral and neuropathological data for a new double-transgenic
mouse model for AD. This study has important implications for understanding the effects
of new therapeutic medications on the behavior of those suffering from AD. Various
therapeutic techniques have already shown productive in AD mouse models. When
administered early in the AD course of a Tg2576 transgenic mouse model, ibuprofen, a
non-steroidal anti-inflammatory drug (NSAID), has led to a significant delay in amyloid
deposition (G. P. Lim et al., 2000). It was also found that antioxidants including
melatonin (Matsubara et al., 2003), curcumin (G. P. Lim et al., 2001), vitamin C/E
(Harkany et al., 1999), blueberry extract (Joseph et al., 2003), and pomegranate juice
(Richard E Hartman et al., 2006) reduced Aβ levels in Tg2576 mice.
Lastly, APOE mimetics have shown to be effective in AD mouse models. ApoE
mimetics are small peptides, derived from the receptor-binding region of APOE, that
mimic the neuroprotective, anti-oxidant, and anti-inflammatory properties of intact APOE
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(Aono et al., 2003; Croy, Brandon, & Komives, 2004; D T Laskowitz et al., 2001; Lynch
et al., 2003, 2005; McAdoo et al., 2005). ApoE133-149 (COG133) is a 17-amino-acid
peptide that has demonstrated in vivo anti-inflammatory and neuroprotective activity in
animal models of AD (Vitek et al., 2012), TBI (Lynch et al., 2005), and hypoxicischemic injury (HIE; McAdoo et al., 2005). Starting at 9 months, Vitek et al. (2012)
administered COG133 subcutaneously 3 times per week for 3 months to CVND-AD
(SwDI-APP/NOS2-/-) transgenic mice. Following treatment, these animals maintained
significantly more of their neurons, grew fewer plaques and neurofibrillary tangles, and
navigated better in the radial arm water maze than did untreated animals (Vitek et al.,
2012). COG1410, a shorter analogue to COG133, is a 12-amino-acid peptide that is also
active in animal models, but with increased potency and extended latency between injury
and time to treatment (D. T. Laskowitz, Fillit, Yeung, Toku, & Vitek, 2006; Daniel T
Laskowitz et al., 2007). ApoE mimetics represent a novel therapeutic strategy to
neurological disorders including AD.
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CHAPTER FOUR
DESIGN
Animals
Transgenic mice expressing human amyloid precursor protein (APP) with a
mutation (V717F) that causes early onset familial Alzheimer’s disease (AD) were
crossbred with transgenic mice expressing human apolipoprotein E (E3 or E4) to create
double-transgenic mice (PDAPP:E3 and PDAPP:E4). Initially, 30 PDAPP:E3 and 16
PDAPP:E4 double-transgenic mice, 21-24 months of age, were obtained from Eli Lilly
Corporation. They were housed on a 12:12 light:dark schedule and fed standard rodent
chow and water ad libitum. These mice underwent a battery of behavioral and cognitive
tests that was approved by Loma Linda University Institutional Animal Care and Use
Committee (IACUC), including the rotarod (assessing balance and sensorimotor
coordination), open field (assessing general activity levels and movement patterns),
elevated zero maze (assessing general anxiety levels), and water maze (assessing learning
and memory). The brains of a subset of these mice were assessed in the current study (n =
5 PDAPP:E3; n = 4 PDAPP:E4; all males).

Tissue Processing and Histology
Animals were sacrificed via intra-cardiac perfusion. The brains were removed and
immersed in paraformaldehyde, fixed in a 30% sucrose solution at 4ºC for about 18
months, and then frozen on dry ice and stored at -20ºC. Coronal sections, 50 microns
thick, were sectioned from the brains’ anterior (prefrontal cortex [PFC]) to the posterior
(cerebellum) using a cryostat. Coronal sections are taken along the frontal plane of the
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brain, dividing the brain into anterior and posterior portions. The free-floating sections
were preserved by placing them in a solution of 400 mL phosphate buffer solution (PBS),
400 mL sodium azide (NaN3), and 3,000 mL double distilled water (ddH2O). Each well
contained four to five anterior, middle, and posterior slices from each brain.
A subset of free-floating sections was stained for diffuse early stage Aβ deposits
(pre-clinical) using HJ3.4, an antibody that binds to the 1st 13 amino acids of Aβ’s Nterminus (i.e., Aβ1-13) and has a fluorescent tag (Tran, Sanchez, Esparza, & Brody,
2011). These plaques lack a morphologically identifiable substructure, resembling a ball
of cotton (Dickson & Vickers, 2001). HJ3.4 staining began with thoroughly washing the
sections in PBS. To enhance antigen (e.g., Aβ) binding, the sections were blocked at
room temperature in a humid chamber in 1% bovine serum albumin (BSA) in PBS 2 x 10
minutes for 90 minutes. BSA enhances antigen detection by binding to and blocking
other epitopes (binding sites). The sections were then incubated overnight at 4ºC with
HJ3.4 antibody (1:1000) in 0.25% BSA/0.25% TritonX-100 in PBS. TritonX-100 is a
detergent used to enhance antibody penetration during immunohistochemistry by acting
as a surfactant (reduces surface tension of a liquid in which it is dissolved). Following
another thorough wash in PBS 2 x 10 minutes and ddH20 2 x 1 minute (to remove PBS
salts), sections were mounted on Superfrost slides and allowed to dry. About 20
microliters of Vectashield, a mounting medium that prevents photobleaching, was placed
on each section and disbursed equally with a cover slip placed over it. Once dry, clear
nail polish was used around the edges of the coverslip to hold it in place. The Vectashield
contained 4’,6-diamidino-2-phenylindole (DAPI), a fluorescent stain that stains DNA in
cell nuclei. DAPI was used to analyze the cellular count of the tissue. The slides were
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then stored in 4ºC. Figure 6 illustrates the HJ3.4 staining of diffuse Aβ in the
hippocampus of a PDAPP:E4 mouse from the current study.

Figure 6. HJ3.4 staining of diffuse deposits in the hippocampus of a PDAPP:E4 double
transgenic mouse from the current study.

Another subset of brain sections was stained for fibrillar (late stage “amyloid”)
Aβ plaques using thioflavin-S. These mature amyloid plaques have a dense core (A. E.
Roher et al., 2004) that can be identified by their compacted central mass of β-amyloid
(Dickson & Vickers, 2001) surrounded by neuritic processes (i.e., injured
axons/dendrites). Figure 7 illustrates fibrillar Aβ deposits stained with thioflavin-S in
transgenic mice. Figure 8 illustrates fibrillar Aβ as well, in pomegranate-treated mice.
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Figure 7. A. Thioflavin-S staining compact deposits in CA1 of the hippocampus of
APPV717F+/+ APOE-/- transgenic mice. Scale bar = 100µm (Irizarry et al., 2000). B.
Thioflavin-S positive amyloid plaque. Scale bar = 20 µm (Oakley et al., 2006). C.
Coronal sections of the dorsal hippocampus stained with Thio-S. (Groen et al., 2003).

Figure 8. Brain Aβ load. Brains from mice treated with control and pomegranate juice.
Mice treated with pomegranate juice had significantly total Aβ (top row) and fibrillar
(thioflavin-S-positive) Aβ (bottom row) in the hippocampus and dorsal cortex than the
control mice (Richard E Hartman et al., 2006).
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Assessing these two stages of plaques not only allows us to differentiate between early
and end stages of Aβ plaques in AD, but to determine whether our hypotheses hold true
for both stages of Aβ plaques.
Thioflavin-S staining began by thoroughly washing sections in PBS and then in
ddH2O to remove PBS and acclimate to the ddH2O. Ethanol (EtOH) was used to
dehydrate the sections. The sections were then stained with a solution of 1% thioflavin-S.
To clean any excess stain, the sections were then washed with ddH2O. After staining for
thioflavin-S, the sections were mounted onto slides and allowed to dry. About 20
microliters of Vectashield was placed on each section and disbursed equally with a cover
slip placed over it. Once dry, clear nail polish was used around the edges of the coverslip
to hold it in place. The slides were then stored in 4ºC.

Aβ Quantification and Cellular Density
For quantification of Aβ, histology slides were initially evaluated using a Zeiss
LSM 710 confocal microscope, provided by the Loma Linda University School of
Medicine Advanced Imaging and Microscopy Facility. Due to unforeseen technical
difficulties, imaging of Aβ deposits was completed using an Olympus FluoView FV1000 confocal microscope, provided by Dr. Hongwei Dong of Zilkha Neurogenetic
Institute at the Keck School of Medicine of University of Southern California.
Images of the entire extent of the hippocampus and dorsal cortex (defined as
cortical tissue directly over the dorsal hippocampus) were assessed at 40x magnification.
ImageJ, an image processing and analysis software, and Adobe Photoshop were used to
quantify fibrillar and total Aβ load, defined as the percentage of each tissue section
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covered by deposits. The Aβ load was calculated by dividing the total area of tissue
covered by deposits (quantified in ImageJ) by the total area of the region of interest
(hippocampus or dorsal cortex; quantified in Adobe Photoshop).
For quantification of cellular density, histology slides were evaluated using a
Keyence BZ-X700 Fluorescence Microscope, provided by Dr. Andre Obenaus’ NonInvasive Imaging Laboratory in the Radiation Biology Program at Loma Linda
University. Images of the hippocampus and dorsal cortex were assessed at 40x
magnification. Images were taken of three areas in the hippocampal CA1 region (CA1-A,
CA1-B, and CA1-C; Figure 9a) at three depths (approximately every 7.5 µm below the
surface of the 50 µm thick tissue sections; Figure 10). Cells were quantified for each
layer using the “cell counter” plugin in ImageJ and summed together. This sum was then
divided by the volume of the CA1 to determine the cellular density in cells/mm3. The
same procedure was done for the dorsal cortex region (DCx-A, DCx-B, and DCx-C;
Figure 11a).
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Figure 9. A. CA1-A, CA1-B, and CA1-C along the CA1 region of animal “5-4,” a
PDAPP:E4 mouse. Image taken at 2x magnification. B. CA1-B of the hippocampus of
animal “5-4.” Image taken at 40x magnification. Blue dots indicate stained cell nuclei.
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Figure 10. This is an image of a cross-section of a brain slice to help visualize how the
brain sections were analyzed in the current study. In the current study, the brain section
was 50 um thick. Images were analyzed at three depths (approximately every 7.5 µm
below the surface of the section).

Figure 11. A. DCx-A, DCx-B, and DCx-C in the dorsal cortex (DCx) of animal “5-4,” a
PDAPP:E4 mouse. Image taken at 2x magnification. B. DCx-B of animal “5-4.” Image
taken at 40x magnification. Blue dots indicate stained cell nuclei.
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Statistical Analysis
IBM SPSS Statistics version 20 will be used to analyze the collected data. All
data will be presented as mean +/- standard error of the mean (SEM), and graphs will be
generated using GraphPad version 6.0d. An α-level of .05 will be used for all significance
tests. For the Aβ load analysis, independent-samples t-tests were conducted to compare
the total Aβ load in HJ3.4-stained PDAPP:E4 and PDAPP:E3 brain sections in the
hippocampus and dorsal cortex. Independent-samples t-tests were also conducted to
compare fibrillar Aβ (amyloid) load in thioflavin-S-stained brain sections. Although two
t-tests were performed, a bonferroni correction was not used since previous research has
shown that two t-tests are not enough to cause a real problem with type I error.
An independent samples t-tests was also used to test between-group differences of
cellular density of PDAPP:E4 and PDAPP:E3 mice in the CA1 and dorsal cortex. An
independent t-test was first conducted to analyze the total cellular density from two areas
of the CA1 or dorsal cortex as a function of APOE type. A multivariate analysis of
variance (MANOVA) was then conducted to determine whether cell densities between
PDAPP:E4 and PDAPP:E3 mice in the CA1 or dorsal cortex still differed when the two
areas within the region were analyzed separately. For the CA1 analyses, an independent
samples t-test was then conducted to determine whether there was a significant difference
between the cellular density in PDAPP:E4 and PDAPP:E3 mice in only CA1-C.
Lastly, for determining whether there is a correlation between neuropathology and
behavioral deficits, bi-correlation analysis will be used to measure the strength and
direction of the relationship between neuropathology and behavioral deficits.
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A total of 9 animals (E3 n = 5; E4 n = 4) will be assessed. Sections stained with
HJ3.4 and thioflavin-S will be included for each animal. Independent-samples t-tests
were conducted to compare the total Aβ load in HJ3.4-stained PDAPP:E4 and PDAPP:E3
brain sections in the hippocampus and dorsal cortex. The probability that the independent
samples t-test will find statistically significant differences in Aβ load and cellular count
in the two groups, given that a difference exists, is 71% (power = 0.71; effect size = 0.8; α
= 0.05; n = 9). Given that a specific direction is hypothesized (i.e., that PDAPP:E4 mice
will show significantly more Aβ staining than PDAPP:E3 mice) a one-tailed test will be
used. Regarding the third hypothesis, power analysis showed that studying nine animals
would give a statistical power sufficient to have a 97% chance of detecting a correlation
between neuropathology and behavioral deficits. Outliers, defined as any data point that
fell within a distance of three times the interquartile range from the first and third
quartiles, were removed.
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CHAPTER FIVE
RESULTS
Given that the following analyses were based on planned comparisons,
Bonferroni corrections were not used for Hypothesis One, Two, or Three.

Hypothesis One
One PDAPP:E3 mouse was removed from the overall Aβ analysis for being 1.6
standard deviations above the hippocampal mean and 1.8 standard deviations above the
dorsal cortex mean. Two PDAPP:E3 mice were removed from the dorsal cortex fibrillar
Aβ analysis, one for being 1.6 standard deviations above the mean and another one for
being 1.1 standard deviations below the mean.
The hypothesis that PDAPP:E4 mice would have more Aβ plaques (total and
fibrillar) in their brains than PDAPP:E3 mice was partially confirmed. A trend was
observed in the hippocampus suggesting that PDAPP:E4 mice had more total Aβ load
(defined as the % area stained by HJ3.4) than PDAPP:E3 mice (PDAPP:E4 M=3.023%,
SD=2.232; PDAPP:E3 M=.875%, SD=.738; t(6)=-1.827, p>.1; Figure 12a). A significant
difference was found in the dorsal cortex suggesting PDAPP:E4 mice had more total Aβ
load than PDAPP:E3 mice (PDAPP:E4 M=2.19%, SD=1.055; PDAPP:E3 M=.533%,
SD=.230; t(6)=-3.069, p<.02; Figure 12b). However, levels of fibrillar Aβ (amyloid) did
not differ between the groups.
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Figure 12. A. There was no significant difference in total Aβ hippocampal load between
HJ3.4-stained PDAPP brain sections expressing human E4 and those expressing human
E3. B. HJ3.4-stained PDAPP:E4 brain sections had a significantly greater total Aβ load
in the dorsal cortex than PDAPP:E3 sections. Note: *p<.025. Data points in red are
outliers excluded from analysis.

Interestingly, amyloid load in both the hippocampus and dorsal cortex was lower
in PDAPP:E4 mice than in PDAPP:E3 mice, although the difference was not significant
(Hippocampus: PDAPP:E4 M=.5%, SD=0.215; PDAPP:E3 M=1.42%, SD=.991; t(7)=1.8,
p>.10; Dorsal cortex: PDAPP:E4 mice M=.833%, SD=0.353; PDAPP:E3 M=.897%,
SD=.055; t(5)=.305, p>.6; Figures 13a and 13b, respectively).
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Figure 13. A. No significant difference in fibrillar Aβ load in the hippocampus or B.
dorsal cortex only out of thioflavin-S-stained animals between PDAPP:E4 and
PDAPP:E3 brain sections. Data points in red are outliers excluded from analysis.
Given that only one statistically significant difference was found in assessing
whether expression of human APOE will alter plaque load in the hippocampus and dorsal
cortex of PDAPP mice, the fibrillar Aβ:total Aβ ratio was analyzed. The previously
excluded outliers were included in this analysis to assess the overall fibrillar β:total Aβ
ratio for each group of mice. The ratios were analyzed by calculating the sum of the
fibrillar Aβ load and total Aβ load in the hippocampus and dorsal cortex to determine
whether there was a statistically significant difference between PDAPP:E4 and
PDAPP:E3 mice (Table 3).

Table 3. Overall fibrillar Aβ:total Aβ ratio.
Genotype
Hippocampus
Dorsal Cortex
PDAPP:E4
0.17
0.38
PDAPP:E3
0.93
0.74

Both Regions
0.26
0.84

Findings indicated both groups of mice had a higher total Aβ load than fibrillar Aβ load,
as expected, in both the hippocampus and dorsal cortex. Also, in both regions, a trend
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indicates that PDAPP:E4 mice have a lower fibrillar Aβ:total Aβ ratio (Ratio=0.26) than
PDAPP:E3 mice (Ratio = 0.84).
To summarize the results of Hypothesis One, PDAPP:E4 mice had more total Aβ
than PDAPP:E3 mice in both the hippocampus and dorsal cortex, although only the
cortical difference was statistically significant. In contrast, PDAPP:E4 mice had less
fibrillar Aβ than PDAPP:E3 mice in both the hippocampus and dorsal cortex, although
neither difference was statistically significant. Lastly, a trend indicates that PDAPP:E4
mice have a lower fibrillar Aβ:total Aβ than PDAPP:E3 mice.

Hypothesis Two
The hypothesis that PDAPP mice that also express human E4 will have a lower
cellular density in their CA1 and dorsal cortices than PDAPP mice that also express
human E3 was partially confirmed. Specifically, PDAPP:E4 mice had a lower cellular
density than PDAPP:E3 mice in the CA1 and dorsal cortex, but the difference was not
statistically significant.
Since the cellular densities for CA1-A (the most lateral area in the CA1; Figure
9a) were very similar between PDAPP:E4 and PDAPP:E3 mice (not statistically
different), only CA1-B and -C were included in the analyses. The cellular density from
CA1-B and -C were summed together and then divided by the CA1 volume to get the
total CA1 cellular density. As hypothesized, PDAPP mice that also expressed E4 had a
lower cellular density in the CA1 than PDAPP mice that also expressed E3 (PDAPP:E4
M=201,132.61 cells/mm3, SD=49,021.35; PDAPP:E3 M=259,563.30 cells/mm3,
SD=51,498.67; t(6)=1.56, p<.17), although the difference was not statistically significant.
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When determining whether the cellular density between PDAPP:E4 and
PDAPP:E3 mice in the CA1 still differed when CA1-B and -C were analyzed separately,
PDAPP:E4 mice still had a lower cellular density in CA1-B and -C separately than
PDAPP:E3 mice (CA1-B: PDAPP:E4 M=108,034.20 cells/mm3, SD=16,741.02;
PDAPP:E3 M=126,861.45 cells/mm3, SD=12,967.54; CA1-C: PDAPP:E4 M=93,098.41
cells/mm3, SD=14,774.98; PDAPP:E3 M=132,701.85 cells/mm3, SD=11,444.65;
F(2,5)=2.23, p<.21; Wilk’s ∆=.53; Figure 14). However, the difference was not
statistically significant.

Figure 14. PDAPP:E4 mice had a lower cellular density in CA1-B and -C of the
hippocampus separately than PDAPP:E3 mice, but the difference was not statistically
significant.

When assessing the difference between the cellular density in PDAPP:E4 and
PDAPP:E3 mice in CA1-C only, findings suggested that PDAPP:E4 mice still had a
lower cellular density in CA1-C (medial), but the difference was not statistically
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significant (PDAPP:E4 M=93,098.41 cells/mm3, SD=21,951.43; PDAPP:E3
M=132,701.85 cells/mm3, SD=27,228.98; t(6)=2.12, p<.08; Figure 15).

Figure 15. PDAPP:E4 mice had a lower cellular density than PDAPP:E3 mice in CA1-C
of the hippocampus, but the difference was not statistically significant.

A non-parametric test (Kruskal Wallis) was conducted to determine whether a
statistically significant difference could be found with CA1-B and -C combined when
accounting for the small sample size. The Kruskal Wallis test corroborated these results
(CA1-B: χ2(1)=1.09, p<.30; CA1-C: χ2(1)=2.69, p<.11).
The cellular density in the dorsal cortex was assessed next. Since cellular
densities for DCx-C (the most medial area in the dorsal cortex; Figure 11a) were very
similar between PDAPP:E4 and PDAPP:E3 mice (not statistically different), only DCx-A
and -B were included in the analyses. The cellular density from DCx-A and -B were
summed and then divided by the total cortical volume to get a total cortical cellular
density. PDAPP mice that also expressed E4 had a lower cellular density in the dorsal
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cortex than PDAPP mice that also expressed E3 (PDAPP:E4 M=461,209.30 cells/mm3,
SD=146,835.99; PDAPP:E3 M=533089.43 cells/mm3, SD=218,760.67; t(6)=.50, p<.64),
although the difference was not statistically significant.
Next, we determined whether cellular density between PDAPP:E4 and PDAPP:E3
mice in the dorsal cortex differed when DCx-A and -B were analyzed separately.
Transformational analyses were used to include the previously excluded outliers by
taking the square root of each value. Findings suggested a trend such that PDAPP:E4
mice had a lower cellular density than PDAPP:E3 mice in DCx-A and DCx-B (DCx-A:
PDAPP:E4 M=459.32 cells/mm3, SD=47.18; PDAPP:E3 M=503.51 cells/mm3,
SD=36.54; DCx-B: PDAPP:E4 M=491.61 cells/mm3, SD=72.28; PDAPP:E3 M=507.82
cells/mm3, SD=55.99; F(2,5)=.33, p>.73; Wilk's ∆=.883; Figure 16), although the
difference was not statistically significant.

Figure 16. There were no statistically significant differences in cellular density between
PDAPP:E4 and PDAPP:E3 mice within DCx-A and –B following a transformational
analysis. However, a trend suggested that PDAPP:E4 mice had a lower cellular density
than PDAPP:E3 mice.
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A non-parametric test (Kruskal Wallis) was conducted to determine whether a
statistically significant difference could be found when accounting for the small sample
size. These results also suggested no statistically significant difference in the cellular
density in DCx-A or -B between PDAPP:E4 and PDAPP:E3 mice (DCx-A: χ2(1)=.20,
p>.65; DCx-B: χ2(1)=.02, p>.88).
To summarize the results of Hypothesis Two, PDAPP:E4 mice had a lower
cellular density than PDAPP:E3 mice in the CA1 and dorsal cortex, although not
statistically significant (Table 4).

Table 4. Means and standard deviations from Hypothesis Two analyses.
PDAPP x ApoE4
Cell Count

PDAPP x ApoE3
Cell Count

Area of
pRegion
M
SD
M
SD
value
CA1-B and Hippocampus C combined
430
101.43 558.6 58.76
0.06
CA1-B only
237.33 61.81 279.6 21.45
0.20
CA1-C only
192.67
40.5
279
54.52
0.06
DCx-A and Dorsal Cortex B combined 1101.33 45.08 961.8 426.36 0.51
DCx-A only
547
44.17 573.2 125.29 0.69
DCx-B only
587.67 46.09 538.2 195.45 0.69
Note. ¥ = Transformational analyses were conducted such that the square root was
taken of each value
Tissue Region

Hypothesis Three
The hypothesis that mice with more Alzheimer’s-like neuropathology
(specifically Aβ plaques and/or lower cellular density) will have worse behavioral
deficits was confirmed.
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Correlation analyses were conducted to determine whether the degree of
neuropathology was correlated with behavioral performance. In PDAPP:E3 mice, a
higher amyloid load in the dorsal cortex was associated with less activity in the open field
tasks (average distance traveled: r=.95, p<.02; Figure 17; average duration traveled:
r=.92, p<.03; Figure 18).

Figure 17. In PDAPP:E3 mice, a higher amyloid load in the dorsal cortex was associated
with less distance traveled in the open field task (r=.95, p<.02).
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Figure 18. In PDAPP:E3 mice, a higher amyloid load in the dorsal cortex was associated
with time spent moving in the open field task (r=.92, p<.03).

Interestingly, across both groups of mice, a higher amyloid load in the dorsal
cortex trended toward an association with better performance on the rotarod task,
although the correlation was not statistically significant (r=.65; p>.05; Figure 19a). When
breaking up the regions by stain and APOE allele, other statistically significant
correlations were found. Specifically, a higher total Aβ load in the hippocampus among
PDAPP:E3 mice was associated with better performance on the rotarod when rotating at
a steady rate (r=.88, p<.05; Figure 19b). Among PDAPP:E4 mice, a higher total Aβ load
in the dorsal cortex was associated with worse performance on the rotarod when rotating
at an accelerated rate (r=-.97, p<.04; Figure 19c) and when rotating at a faster accelerated
rate (r=-.97, p<.03; Figure 19d), following transformational analysis consisting of taking
the square root of each value.
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Figure 19. A. Across both groups of mice, a higher amyloid load in the dorsal cortex
trended toward an association with better performance on the rotarod task, although the
correlation was not statistically significant (r=.65; p>.05). B. Among PDAPP:E3 mice, a
higher total Aβ load in the hippocampus was statistically significantly correlated with
better performance on the rotarod when rotating at a steady rate (r=.88, p<.05). C.
Among PDAPP:E4 mice, a higher total Aβ load in the dorsal cortex was statistically
significantly correlated with worse performance on the rotarod when rotating at an
accelerated rate (r=-.97, p<.04) and D. when rotating at a faster accelerated rate (r=-.97,
p<.03) following transformational analyses consisted of taking the square root of each
value.

There were no significant correlations between total Aβ load or amyloid load in
the dorsal cortex or hippocampus with water maze or zero maze performance.
Correlation analyses were then conducted to determine whether cellular densities
in the CA1 or dorsal cortex were correlated with behavioral deficits. Findings suggested a
statistically significant correlation, such that a lower cellular density in the CA1 was
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associated with worse performance during the probe trials (a lower percent time in the
target quadrant; r=-.81, p<.02; Figure 20) of the water maze. Additionally, a trend
suggested that lower cellular density in the CA1 was associated with worse performance
(traveling a greater distance) in the cued task (r=-.69, p<.059; Figure 21) and in the
spatial task (r=-.63, p<.094; Figure 22). There were no significant correlations between
the cellular density in the CA1 and any other behavioral performance. There were no
significant correlations between total cellular density in the dorsal cortex and any
behavioral performance.

Figure 20. Across both groups of mice, lower cellular density in the CA1 was
associated with worse performance (lower percent time in the target quadrant) during the
probe trials of the water maze (r=-.81, p<.02).
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Figure 21. Across both groups of mice, lower cellular density in the CA1 was associated
with worse performance (traveling a greater distance) in the cued task of the water maze
(r=-.69, p<.059).

Figure 22. Across both groups of mice, lower cellular density in the CA1 was associated
with worse performance (traveling a greater distance) in the spatial task of the water
maze (r=-.63, p<.094).
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Correlation analyses revealed no relationships between Aβ or amyloid load and
cellular density in the CA1 and dorsal cortex. There were also no statistically significant
correlations between fibrillar Aβ and total Aβ.
Repeated measures analyses suggested that PDAPP:E4 mice had more severe
spatial learning deficits than PDAPP:E3 mice (Figure 23), as corroborated by Figure 22.
PDAPP:E4 mice also spent more time in the open quadrants of the zero maze than
PDAPP:E3 mice (F(1,7)=5.99, p<.045; Figure 24).

Figure 23. Repeated measures analyses suggested that PDAPP:E4 mice had worse spatial
learning performance than PDAPP:E3 mice.

73

Figure 24. PDAPP:E4 mice spent more time in the open quadrants (less time in the dark)
in the zero maze compared to PDAPP:E3 mice (p<.05).
To summarize the results of Hypothesis 3, PDAPP mice expressing E4 had worse
behavioral deficits than PDAPP mice expressing E3, which correlated with their
Alzheimer’s-like neuropathology. In both sets of mice, those with more Alzheimer’s-like
neuropathology (specifically Aβ plaques and/or lower cellular density) had worse
behavioral deficits.
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CHAPTER SIX
DISCUSSION
The current study was designed to test the hypothesis that PDAPP:E4 mice would
have greater neuropathology (including greater Aβ plaque load and lower cellular density
in the brain) than PDAPP:E3 mice. Based on previous literature, the presence of E4 leads
to greater Aβ production than does E3 in transgenic mice and humans (Bales et al., 1999,
2009; Mahley, Weisgraber, & Huang, 2006; Schmechel et al., 1993; Tiraboschi et al.,
2004; Ye et al., 2005). Also, Hartman et al. (2002) concluded that in the presence of
traumatic brain injury, fibrillar Aβ was only present in the PDAPP:E4 mice and not the
PDAPP:E3 mice.
Previous studies have shown that Aβ aggregation induces cell death (Estus et al.,
1997; LaFerla, Hall, Ngo, & Jay, 1996; Loo et al., 1993). Hippocampal cell loss has also
been reported in AD patients (Mann, 1996; West, Coleman, Flood, & Troncoso, 1994).
Hippocampal cell loss has also been reported in animal models such as in in vitro rat
(Estus et al., 1997) and mouse (Ji et al., 2002; Loo et al., 1993) AD models as well as in
in vivo mouse (Casas et al., 2004; LaFerla et al., 1996; Schmitz et al., 2004) AD models.
Our findings indicate that PDAPP:E4 brains had more total Aβ (diffuse and
fibrillar Aβ) in the hippocampus and dorsal cortex than PDAPP:E3 brains, and that the
difference was greatest in the dorsal cortex. These findings were corroborated by the
fibrillar Aβ:total Aβ ratio analysis (Table 3). There was no statistically significant
difference in fibrillar Aβ between PDAPP:E4 and PDAPP:E3 brains, but a trend suggests
that PDAPP:E4 brains had less fibrillar Aβ in the hippocampus and dorsal cortex than
PDAPP:E3 brains.

75

Findings also indicated no difference in cellular density between PDAPP:E4 and
PDAPP:E3 brains in the CA1 or dorsal cortex. However, a trend was observed such that
PDAPP:E4 brains had a lower cellular density than PDAPP:E3 brains in the CA1 and
dorsal cortex.
Years of evidence have suggested that Aβ accumulation in the brain is the main
causal factor of AD (Kim et al., 2011; Kuszczyk et al., 2013). One potential explanation
for the trend that PDAPP:E4 brains had less fibrillar Aβ in the hippocampus and dorsal
cortex than PDAPP:E3 brains is that Aβ accumulation may present as part of an adaptive
response to chronic brain stress such as oxidation by free radicals, metabolic
dysregulation, and/or genetic factors. Some studies have even suggested that Aβ is
important for healthy brain functions, and that the removal of Aβ can interfere with brain
homeostasis (Castello & Soriano, 2013; Castello, Jeppson, & Soriano, 2014).
Another potential explanation for the trend found in the current study is that
amyloid accumulation may serve as a neuroprotectant (Castellani et al., 2009). Castellani
et al. (2009) suggests that Aβ is not responsible for the clinical manifestation of AD since
it may protect cells from toxic intermediates. They concluded that since amyloid
accumulation is a byproduct of upstream pathogenic events, it protects cells from the
toxic protofibrils (transient structures during the formation of mature amyloid fibrils) or
oligomers. In other words, the fibrils may be a better alternative to more neurotoxic
smaller aggregates.
The fibrillar Aβ:total Aβ ratio analysis trended toward a lower ratio in PDAPP:E4
mice than in PDAPP:E3 mice, meaning that PDAPP:E4 mice had a lower proportion of
fibrillar Aβ in the total Aβ load than PDAPP:E3 mice. These findings contradict the idea
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that the presence of the apoe4 allele should lead to a greater Aβ accumulation than the
presence of the E3 allele (Ji et al., 2002). However, these data may support the idea that
amyloid accumulation serves a protective role in the brain. Since the E4 allele is
associated with more neurotoxicity than the E3 allele, they serve less as a neuroprotectant.
However, it is possible that the HJ3.4 stain was not potent enough or that the thioflavin-S
staining protocol yielded too much background staining.
The current study also tested the hypothesis that mice with more Alzheimer’s-like
neuropathology (specifically Aβ plaques and/or lower cellular density) will have worse
behavioral deficits. Hartman et al. (2005) found that Aβ plaques displayed in PDAPP
mice contributed to behavioral deficits. Similarly, G. Chen et al. (2000) found a negative
correlation between spatial learning capacity and plaque burden for PDAPP mice.
The current study found that PDAPP:E4 mice had worse behavioral deficits than
PDAPP:E3 mice, and that these deficits were positively correlated with the degree of
neuropathology. Several studies corroborate our findings such that amyloid load in mice
is correlated with greater deficits in spatial learning tasks (G. Chen et al., 2000, Hartman
et al., 2005, Hartman et al., 2006). Hartman et al., 2005 showed that these spatial learning
deficits were ameliorated after treating transgenic mice with an antibody specific for
human Aβ. Hartman et al., 2006 also showed that dietary supplementation with
pomegranate juice decreased amyloid load and improve behavioral performance in
transgenic mice.
For example, higher amyloid plaque loads in the dorsal cortex of PDAPP:E3 mice
were associated with lower activity levels (distance moved [Figure 17] and duration spent
moving [Figure 18]) in the open field task. PDAPP:E3 mice also showed lower activity
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levels in the zero maze, spending a lot of time in the dark. Although PDAPP:E3 mice
spent more time in the dark than PDAPP:E4 mice, PDAPP:E3 still spent a relatively
lower duration of time in the dark compared to control wild type mice who spend about
2/3rds of that time in the dark.
The current study also found that higher total Aβ loads in the hippocampi of
PDAPP:E3 mice were correlated with better performance on the rotarod rotating at a
steady rate, and higher total Aβ loads in the dorsal cortices of PDAPP:E4 mice were
correlated with worse performance on the rotarod rotating at an accelerated rate.
Contradictory to previous literature, one possible explanation for these results may be
that Aβ accumulation may serve as a neuroprotective factor (e.g., by protecting cells from
toxic protofibrils or oligomers) up until a substantial amount of balance and sensorimotor
coordination is required (balancing on a rod rotating at an accelerated rate) in which case
behavior declines, as observed in the findings.
Correlation analyses between cell count and behavioral deficits confirmed that
mice with more Alzheimer’s-like neuropathology have more behavioral deficits.
Specifically, the degree of lower cellular density was positively correlated with deficits in
spatial learning and memory. Similar findings were reported by Morris & Price (2001), in
which they observed substantial cell loss in humans with mild AD. Multiple other studies
then found that those with AD have behavioral deficits (Chen et al., 2000; Hartman et al.,
2005), providing evidence for the positive correlation between cell loss and behavioral
deficits.
PDAPP:E4 mice had more spatial learning deficits, spent more time in the open
quadrants of the zero maze, and had worse performance on the rotarod than PDAPP:E3
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mice. These findings were likely due to motor deficits and/or abnormal exploratory/risktaking behaviors.

Limitations
One main limitation of the current study is the low sample size. Many animals
could not be included in the histological analysis due to high levels of old-age related
mortality that often occurred overnight, rendering the brains difficult or impossible to
process. This, in addition to the exclusion of outliers, yielded a low sample size that
likely played a strong influence on high degree of variance observed. Further research is
encouraged with a larger sample size.

Conclusion
The hypotheses for the current study, based on clinical observations in humans,
was that PDAPP:E4 mice would have more Aβ plaques and lower cellular density in the
CA1 and dorsal cortex than PDAPP:E3 mice, and that higher levels of neuropathology
would be correlated with worse behavioral deficits.
The findings from the current study partially corroborated those from Bales et al.,
1999 & 2009 in that diffuse Aβ was significantly greater in PDAPP:E4 mice than in
PDAPP:E3 mice in the hippocampus and cortex. Although Bales et al., 1999 & 2009 also
reported significant differences in fibrillar Aβ, the difference was not significant in the
current study. The current study’s novel findings include significantly worse behavioral
performance in the PDAPP:E4 mice, as well as a trend for PDAPP:E4 mice to have fewer
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cells per volume in both the hippocampus and cortex. Mice with more Alzheimer’s-like
neuropathology generally had worse behavioral deficits.
As illustrated in Table 5, various animal models for AD have been studied. The
animal model from the current study (second to last row; Table 5) is the exact same
animal model as the one studied in Bales et al., 1999 & 2009 (third to last row; Table 5.)
The PDAPP:E mice in this study replicate several features of Alzheimer’s disease
(last row; Table 5), and may therefore be a good model for studying how apoE genotype
affects the development of the disease’s neuropathological and behavioral sequelae and
its response to therapeutic treatments, especially those designed to reduce plaque
accumulation.
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Table 5. Summary of findings of various types of AD models and how they compare to
the findings of the current study.
CA1
Dorsal Cortex
Lower
Lower
Diff. Fibr.
Cell
Diff. Fibr.
Cell
Beh.
Model
Study Aβ
Aβ Density Aβ
Aβ Density Tau Deficits
Humans
✓
✓
✓
✓
✓
✓
✓
✓
with AD
A
PDAPP
B
✓
✓
✓
✓
✓
✓
✓
✕
APP23,
APP751,
Tg2576,
APP695,
TG Mice
Human E4
Mice
PSAPP,
TASTPM
Mice
PDAPP:E4
Mice
PDAPP:E4
Mice (KI)

C

✓

✓

✓

✓

✓

✕

✓

✓

D

✓

✓

✕

✓

✓

✕

✓

✓

E

✕

✓

✓

✕

✓

✓

✓

✓

F

✓

✓

✕

✕

✕

Trend

N/A

Trend

G

✓

✓

N/A

✓

✓

N/A

N/A N/A

Current
Model:
PDAPP:E4
✓
✓
✓
Mice
H
Trend
Trend N/A
✕
✕
Combined
✓
✓
✓
✓
✓
Model
I
Trend
Trend N/A
Note. "Diff." = diffuse, "Fibr." = fibrillar, "Beh." = Behavioral, ✓= Present, ✕= Absent,
N/A = Not Tested; A. Bookheimer et al. 2000, Braak & Braak, 1995, Burggren et al.,
2008, Corder et al., 1993, & Schmechel et al., 1993; B. Duyckaerts et al., 2007, Games et
al., 1995; German et al., 2005; Holtzman et al., 2000; C. Calhoun et al., 1998, Hartman et
al., 2006, Hsiao et al., 1996, & Schmitz et al., 2004, Tomidokoro et al., 2001; D. Buttini
et al., 2002, Grootendorst et al., 2005, Raber et al., 2004, Tesseur et al., 2000, &
Tiraboschi et al., 2004; E. Holcomb et al., 1998, Howlett et al., 2008, & Takeuchi et al.,
2000; F. Fagan et al., 2002 & Hartman et al., 2002; G. Bales et al., 1999 & Bales et al.,
2009; H. Current study; I. Bales et al., 1999, Bales et al., 2009, & Current study.
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